US20210007753A1 - Electrolytic detachment with fluid electrical connection - Google Patents

Electrolytic detachment with fluid electrical connection Download PDF

Info

Publication number
US20210007753A1
US20210007753A1 US16/948,740 US202016948740A US2021007753A1 US 20210007753 A1 US20210007753 A1 US 20210007753A1 US 202016948740 A US202016948740 A US 202016948740A US 2021007753 A1 US2021007753 A1 US 2021007753A1
Authority
US
United States
Prior art keywords
electrode
implant
delivery
detachment zone
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/948,740
Inventor
Vincent Divino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covidien LP
Original Assignee
Covidien LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covidien LP filed Critical Covidien LP
Priority to US16/948,740 priority Critical patent/US20210007753A1/en
Assigned to COVIDIEN LP reassignment COVIDIEN LP ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DIVINO, VINCENT
Publication of US20210007753A1 publication Critical patent/US20210007753A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/962Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve
    • A61F2/966Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/12031Type of occlusion complete occlusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A61B17/12113Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214Coils or wires
    • A61B17/12145Coils or wires having a pre-set deployed three-dimensional shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A61B17/12172Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017Electrical control of surgical instruments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831Material properties
    • A61B2017/00867Material properties shape memory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831Material properties
    • A61B2017/00929Material properties isolating electrical current
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • A61B2017/12054Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12063Details concerning the detachment of the occluding device from the introduction device electrolytically detachable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3966Radiopaque markers visible in an X-ray image
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2217/00General characteristics of surgical instruments
    • A61B2217/002Auxiliary appliance
    • A61B2217/007Auxiliary appliance with irrigation system

Definitions

  • the subject technology relates to the delivery of implantable medical devices and systems for delivering implantable medical devices.
  • vascular aneurysms can be occluded with an implantable medical device that is introduced to the vasculature with a delivery wire through a catheter. Once advanced to the treatment site, the medical device can be inserted into the aneurysm cavity to occlude the aneurysm and then detached from the delivery wire.
  • Detachment of a medical device or implant from the delivery wire can be problematic. It is essential that the implant can be collapsed to form as small a profile as possible to be guided through the fine bore of the catheter, and it must bring about a reliable severance of the implant from the wire. Absent a reliable severance of the implant, withdrawal of the delivery wire and catheter may cause unintended removal of the implant from the aneurysm, and thus injure and/or rupture of the wall of the aneurysm or vessel.
  • Electrolytic detachment of an implantable medical device can involve using an electrolytically corrodible region on the end of a delivery wire at the connection between the delivery wire and the medical device.
  • Known methods of electrolytic detachment can employ an electrolytically corrodible region on the end of the delivery wire at the connection between the delivery wire and the implant.
  • the connection of the implant to the delivery wire is limited by the requirements of the electrolytically corrodible region. For example, only materials that have a sufficiently high degree of strength to enable reliable guidance of the implant can be utilized in delivery wire material selection.
  • a delivery system comprising:
  • a method of delivering an implant comprising:
  • positioning the implant comprises:
  • applying the voltage potential comprises:
  • applying the voltage potential comprises applying a voltage potential between the delivery electrode and the infusion electrode.
  • applying the voltage potential comprises applying the voltage potential until the detachment zone has corroded.
  • FIG. 1 shows a perspective view of a delivery system having an electrical return path, in accordance with one or more embodiments of the present disclosure.
  • FIG. 2 shows a perspective side view of a braid ball implant, in accordance with one or more embodiments of the present disclosure.
  • FIG. 3 shows a side-sectional view of the braid ball implant of FIG. 2 deployed within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • FIG. 4 shows a sectional view of a distal end of the delivery system of FIG. 1 , in accordance with one or more embodiments of the present disclosure.
  • FIG. 5 shows a side view of the delivery system of FIG. 1 , in accordance with one or more embodiments of the present disclosure.
  • FIG. 6 shows a sectional view of the delivery system of FIGS. 1 and 5 , in accordance with one or more embodiments of the present disclosure.
  • FIG. 7 shows a partial sectional view of an implant detachment zone at a stage of implant deployment within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • FIG. 8 shows a partial sectional view of an implant detachment zone at a stage of implant deployment within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • FIG. 9 shows a partial sectional view of an implant detachment zone at a stage of implant deployment within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • Implants can be implanted in body cavities, including blood vessels. Implants can be delivered to a target body cavity using a delivery system, and detached from the delivery system when positioned within the body cavity.
  • a delivery system can comprise a delivery wire having an electrolytically corrodible detachment zone between the implant and the delivery system. When a voltage potential is applied across the detachment zone while in an electrolyte, such as blood for example, the detachment zone corrodes. When sufficiently corroded, the detachment zone is severed, releasing the implant from the delivery system.
  • the voltage potential can be generated using a power supply electrically connected to the delivery system.
  • the power supply or ground can be electrically connected to a patient on the surface of the patient's skin to provide a conductive pathway from a detachment zone at or near the implant.
  • the conductive pathway can require a secure connection, such as with a transcutaneous needle or other device that punctures the patient. The current would then flow through the patient and the needle between the detachment zone and the ground or power supply.
  • electrolytic detachment can be facilitated by a closed circuit of electrical current entirely within a delivery system, thereby avoiding the need to insert a needle into the patient to complete a circuit through the patient's tissue.
  • patient comfort is improved and resistance within the circuit is reduced, thereby improving detachment time and reliability.
  • FIG. 1 illustrates a view of a delivery system 10 according to one or more embodiments of the subject technology.
  • the delivery system 10 can include an implant 20 , a pusher assembly 12 , and a delivery catheter 100 connected to a handle 42 .
  • the handle 42 shown provides proximal access to a delivery wire 44 of the pusher assembly 12 that engages the implant 20 at a distal end thereof.
  • the delivery wire 44 can be connected to the implant at a detachment zone 30 forming a detachment junction between the delivery wire 44 and the implant 20 at or near the implant 20 .
  • the delivery catheter 100 can be positioned over the pusher assembly 12 .
  • the power supply 46 can be coupled to a proximal portion of the delivery wire 44 , and the power supply 46 also can be coupled (e.g., to the handle 42 ) such that one of the terminals of the power supply 46 is in electrical connection with a fluid and/or fluid flow 170 in a vicinity of the implant 20 , as described further herein.
  • the power supply 46 can include an electrical generator configured to output medically useful electrical current.
  • the power supply 46 may be a direct current power supply, an alternating current power supply, or a power supply switchable between a direct current and an alternating current.
  • the power supply 46 can include a suitable controller that can be used to control various parameters of the energy output by the generator, such as intensity, amplitude, duration, frequency, duty cycle, and polarity.
  • the power supply 46 can provide a voltage of about 12 volts to about 28 volts and a current of about 1 mA to about 2 mA.
  • a fluid source 150 may be provided in fluid connection with a pump 160 for infusion of the fluid via the delivery catheter 100 .
  • the fluid source 150 can include saline or another sterile, electrolytic, biocompatible solution.
  • the fluid can be infused together with a drug, such as heparin.
  • the pump can draw fluid from the fluid source 150 and advance the fluid into and through a lumen 124 ( FIG. 6 ) of the delivery catheter 100 .
  • the pump 160 can be an infusion pump, a syringe, a compressor, a pressurized container, and/or a gravity-based infusion mechanism.
  • an implant 20 delivered by the delivery system 10 can be a braid ball implant.
  • the implant 20 can be formed from tubular braid stock including a resilient material, such as nitinol, that defines an open volume in an uncompressed/unconstrained state.
  • the size of the implant can be selected to fill an aneurysm 2 when expanded therein.
  • the implant 20 can include a hub 50 and layers 26 , 28 .
  • the hub can be located at a proximal end 53 of the implant.
  • the hub 50 can be fixedly attached to the remainder of the implant 20 .
  • the hub 50 can grasp braided filaments of the layers 26 , 28 of the implant 20 .
  • the implant 20 can include the layers 26 , 28 at least where impacted by flow at the neck 9 of the aneurysm 2 .
  • the implant 20 illustrated herein is a braided ball
  • the implant 20 can be any well-known treatment device including, but not limited to, vasoocclusive coils, stents, filters, or flow diverters.
  • the implant 20 can be set within an aneurysm 2 at a vascular bifurcation 4 , formed by trunk vessel 6 and branch vessels 8 , for example as illustrated in FIG. 3 .
  • the implant 20 can be delivered by access through the trunk vessel 6 (e.g., the basilar artery), preferably through a commercially available microcatheter with a delivery system as detailed below.
  • the pusher assembly 12 is positioned such that the implant 20 can be delivered at least partially into the aneurysm 2 .
  • the implant 20 is separated from the remainder of the pusher assembly 12 by electrolytic corrosion at the detachment zone 30 , and the remainder of the pusher assembly 12 is withdrawn into the delivery catheter 100 .
  • FIG. 4 illustrates a sectional view of a pusher assembly 12 according to one or more embodiments of the subject technology.
  • a pusher assembly 12 includes a delivery wire 44 having a proximal region 31 , a distal region 33 , and a detachment zone 30 between the proximal region 31 and the distal region 33 .
  • the delivery wire 44 can form a single, monolith component across the proximal region 31 , the distal region 33 , and the detachment zone 30 , or the delivery wire 44 can be formed of separate segments joined together.
  • portions of the delivery wire 44 can be coated with a nonconductive material so that only a limited portion of surface area of the delivery wire is exposed to, and in electrical communication with, the electrolyte for corrosion when a voltage potential is applied. Limiting the size of the exposed portion of the surface area of the delivery wire can concentrate electrolytic activity to expedite corrosion through and severance of the delivery wire.
  • a proximal insulating layer 34 can be provided over at least a portion of an outer surface of the proximal region 31 .
  • the proximal insulating layer 34 can circumferentially surround an outer surface of the proximal region 31 extending proximally from a proximal end of the detachment zone 30 to a location at or near a proximal end of the delivery wire 44 .
  • a distal insulating layer 32 can be provided over at least a portion of an outer surface of the distal region 33 extending distally from a distal end of the detachment zone 30 to a distal terminal end of the delivery wire 44 .
  • the distal insulating layer 32 can circumferentially surround and cover the entire outer surface of the distal region 33 .
  • proximal and distal insulating layers 34 , 32 leave exposed the portion of the delivery wire 44 forming the detachment zone 30 between the proximal region 31 and the distal region 33 .
  • the fluid When in contact with a body fluid, such as blood, the fluid serves as an electrolyte allowing current to be focused on the non-coated detachment zone 30 .
  • the proximal and distal insulating layers 34 , 32 prevent exposure of the proximal region 31 and the distal region 33 to the fluid. Accordingly, electrical energy conducted along the delivery wire 44 is concentrated at the detachment zone 30 , thereby reducing the time required to erode away the detachment zone 30 .
  • the proximal and distal insulating layers 34 , 32 can be over-molded, co-extruded, sprayed on, or dip-coated with respect to the proximal region 31 and/or the distal region 33 .
  • the distal insulating layer 32 also prevents electrical connection between the delivery wire 44 and the implant. As shown in FIG. 4 , the distal insulating layer 32 electrically isolates the implant 20 from an electrical current conducted along a length of the delivery wire, from the proximal region 31 to the distal region 33 .
  • a proximal end of the distal insulating layer 32 may be positioned at or proximal to the hub 50 , and a distal end of the distal insulating layer 32 may be positioned at or distal to the hub 50 Likewise, a proximal end of the distal region 33 may be positioned proximal to the hub 50 , and a distal end of the distal region 33 may be positioned within or distal to the hub 50 .
  • the distal insulating layer 32 insulates the distal region 33 from the hub 50 to prevent the electrical current from being conducted to the implant 20 .
  • the proximal and distal insulating layers 34 , 32 can comprise an electrically nonconductive or insulative polymer, such as polyimide, polypropylene, polyolefins, or combinations thereof.
  • the proximal and distal insulating layers 34 , 32 can be applied as a single coating with a portion thereof subsequently removed to expose the detachment zone 30 .
  • Laser ablation can be employed to selectively remove the coating to a controlled length, minimizing the time required to erode through the component. Lengths as small as 0.0005′′ and as large as 0.1′′ or longer can be removed.
  • lengths of detachment zone 30 can be greater than 0.005′′ and/or less than 0.010′′ to provide sufficient exposure to achieve detachment times of less than 30 seconds.
  • the delivery wire 44 (including some or all of the proximal region 31 , the distal region 33 , or the detachment zone 30 ) can comprise one or more of the following materials: ceramic materials, plastics, base metals or alloys thereof, or combinations thereof.
  • Some of the most suitable material combinations for forming the electrolytically corrodible points can include one or more of the following: stainless steels, preferably of the type AISI 301, 304, 316, or subgroups thereof; Ti or TiNi alloys; Co-based alloys; noble metals; or noble metal alloys, such as Pt, Pt metals, Pt alloys, Au alloys, or Sn alloys.
  • the electrolytically corrodible detachment zone can be pre-corroded by etching or other methods.
  • a marker coil 36 is wound helically about an outer surface of the proximal insulating layer 34 .
  • the marker coil 36 can be of a radiopaque material, such as platinum, gold, palladium, iridium, and alloys thereof.
  • the proximal insulating layer 34 can be provided about an outer surface of the marker coil 36 .
  • the proximal insulating layer 34 can extend over an entire length of the marker coil 36 and distally beyond the marker coil 36 , such that every portion of the marker coil 36 is covered by the proximal insulating layer 34 .
  • the delivery wire 44 can be continuous through the proximal region 31 . Accordingly, an electric potential applied to the proximal end of the delivery wire 44 can induce an electrical current conducted through the delivery wire 44 along the proximal region 31 to the detachment zone 30 . Furthermore, an axial force applied to the delivery wire 44 can result in an axial movement of the detachment zone 30 and the implant 20 .
  • FIGS. 5 and 6 illustrate various views of a delivery system 10 according to some embodiments of the subject technology.
  • FIG. 5 depicts a side view of a delivery system 10
  • FIG. 6 depicts a sectional view of the delivery system 10 as shown in FIG. 5 .
  • the delivery system 10 illustrated in FIGS. 5 and 6 is similar in some respects to the delivery system 10 of FIG. 1 and can be understood with reference thereto, where like numerals indicate like elements or components not described again in detail.
  • FIGS. 5 and 6 illustrate electrical connection of a power supply 46 to a delivery wire 44 and a fluid and/or fluid flow 170 in a vicinity of the detachment zone 30 of the delivery wire 44 .
  • An electrical pathway can pass from a first terminal 48 of the power supply to the delivery wire 44 and into a fluid/fluid flow 170 at the detachment zone 30 , and then return to a second terminal 47 of the power supply 46 through the fluid/fluid flow.
  • the delivery catheter 100 can be formed as a generally tubular member with a body extending from a proximal end 110 and terminating in a distal end 112 .
  • An inner lumen 124 extends from a proximal port 45 of the delivery catheter 100 .
  • the delivery catheter 100 can generally track over a conventional guidewire and may be any commercially available microcatheter appropriate for such applications.
  • Inner lumen 124 of the delivery catheter generally has an inner diameter between about 0.01 inch and about 0.098 inch (0.25-2.49 mm). Other designs and dimensions are contemplated.
  • Commercially available microcatheters which may be suitable for use as delivery catheters include the REBARTM Reinforced Micro Catheter, which is available from Medtronic, Inc. and the MARKSMANTM Catheter, which is available from Medtronic, Inc.
  • the proximal port 45 of the delivery catheter 100 may be provided with an adapter (not shown) having a hemostatic valve.
  • the proximal port 45 may comprise a valve or other sealable mechanism for receiving at least a portion of the pusher assembly 12 while preventing passage of the fluid flow 170 proximally past the proximal port 45 in the presence or absence of the delivery wire 44 .
  • the proximal port 45 can include a split septum, slit valve, duckbill valve, dome valve, donut valve, multi-cuspid valve, or combinations thereof.
  • the proximal port 45 can include a hydrophobic coating.
  • the delivery catheter 100 is generally constructed to bridge between a femoral artery access site and a cervical region of the carotid or vertebral artery and may be chosen according to several standard designs that are generally available. Accordingly, the delivery catheter 100 may be at least 85 cm long, and more particularly may be between about 95 cm and about 175 cm long. For example, a distance between (a) the proximal port 45 and/or the infusion port 60 ( FIG. 5 ) and (b) the distal end 112 can be at least 85 cm, and more particularly may be between about 95 cm and about 175 cm long.
  • a delivery electrode 82 is configured to be coupled to the delivery wire 44 .
  • a variety of coupling mechanisms may be employed to selectively secure the delivery electrode 82 to the delivery wire 44 such that an electrical connection is established.
  • the delivery electrode 82 can include a clamp, pin, ring, clasp, or combinations thereof to engage a complementary structure of the delivery wire 44 .
  • the delivery electrode 82 is further configured to be coupled to the first terminal 48 (e.g., cathode or anode) of the power supply 46 .
  • An electrical potential generated at the first terminal 48 can induce an electrical current through the delivery electrode 82 and the delivery wire 44 to the detachment zone 30 .
  • Flow of electrical current between the delivery wire and the immediately surrounding environment e.g., the fluid and/or fluid flow 170
  • At least a portion of the proximal insulating layer 34 may extend to the proximal port 45 and/or proximally thereof to insulate the delivery wire 44 from the fluid flow 170 within the lumen 124 of the delivery catheter 100 .
  • an infusion connector 62 can provide a connection to the infusion port 60 for infusion of fluid and electrical connections.
  • the infusion connector 62 can connect to an interface with the infusion port 60 on a first end.
  • the infusion connector 62 can further provide an electrode connector 140 and a fluid connector 162 .
  • the infusion connector 62 can define a lumen that divides and connects to both an electrode port 142 of the electrode connector 140 and the pump 160 and fluid source 150 of the fluid connector 162 .
  • the entirety or a portion of the infusion connector 62 and components thereof can be located outside a body of the patient.
  • the fluid connector 162 , the electrode connector 140 , the electrode port 142 , the pump 160 , and/or the fluid source 150 can be located outside a body of the patient during use.
  • components interfacing with the infusion connector 62 and components thereof can be located outside a body of the patient.
  • the infusion connector 62 can take the form of a Y-connector. Additional connectors can be provided in addition to the electrode connector 140 and the fluid connector 162 .
  • the interior lumens of the infusion connector 62 provide fluid communication and electrical connection through the fluid and between the infusion port 60 , the electrode port 142 , and the fluid source 150 .
  • the components of the infusion connector 62 can be placed in fluid communication and electrical connection with the lumen 124 of the delivery catheter 100 , as well as components residing in and near the lumen 124 , including the detachment zone 30 .
  • the electrode connector 140 is configured to receive an infusion electrode 80 .
  • at least a portion of the infusion electrode 80 extends distally through the electrode port 142 and at least a portion of the lumen of the electrode connector 140 .
  • the infusion electrode 80 extends through the electrode connector 140 and into the lumen of the infusion connector 62 .
  • the infusion electrode 80 may extend through the infusion connector 62 and through the infusion port 60 .
  • the infusion electrode 80 may extend into the lumen 124 of the delivery catheter 100 such that the distal tip of the infusion electrode 80 terminates within the lumen 124 .
  • the infusion electrode 80 extends distally along the length of the delivery catheter 100 within the lumen 124 such that the distal tip of the infusion electrode 80 terminates within 2 inches of the detachment zone 30 , and in some embodiments within 1 inch of the detachment zone 30 .
  • at least a portion of the infusion electrode 80 between the second terminal 47 and a region adjacent the detachment zone 30 may be electrically insulated so long as the portion of the infusion electrode 80 within 2 inches of the detachment zone 30 is exposed (e.g., in electrical communication with the fluid pathway).
  • the infusion electrode 80 is configured to pass through the electrode port 142 to contact and/or be in electrical connection with the fluid 170 within the infusion connector 62 and/or the delivery catheter 100 .
  • the infusion electrode 80 can comprise a needle or other elongate member.
  • the electrode port 142 may comprise a valve or other sealable mechanism for receiving at least a portion of the infusion electrode 80 while preventing passage of the fluid flow 170 proximally past the electrode port 142 in the presence or absence of the infusion electrode 80 .
  • the electrode port 142 can include a split septum, slit valve, duckbill valve, dome valve, donut valve, multi-cuspid valve, or combinations thereof.
  • the electrode port 142 can include a hydrophobic coating.
  • the infusion electrode 80 can be placed in electrical connection with the fluid 170 without directly contacting the fluid 170 .
  • the infusion electrode 80 can include a clamp, pin, ring, clasp, or combinations thereof to engage the electrode port 142 , thereby placing the infusion electrode 80 in electrical connection with the fluid 170 .
  • the infusion electrode 80 is further configured to be coupled to the second terminal 47 (e.g., cathode or anode) of the power supply 46 .
  • An electrical potential generated at the second terminal 47 can induce an electrical current through the infusion electrode 80 and the fluid 170 (e.g., along the lumen 124 ) to the vicinity of the detachment zone 30 .
  • the infusion electrode 80 can be a “painted” electrode on a surface of a non-conductive material.
  • the infusion electrode 80 can include platinum, platinum alloys (e.g., 92% platinum and 8% tungsten, 90% platinum and 10% iridium), gold, cobalt-chrome, stainless steel (e.g., 304 or 316), and combinations thereof.
  • an electrical pathway can pass through one or more of the first terminal 48 of the power supply 46 , the delivery electrode 82 , the proximal region 31 of the delivery wire 44 , the detachment zone 30 , the fluid 170 in the lumen 124 of the delivery catheter 100 , the fluid 170 in the infusion port 60 , the fluid 170 in the fluid connector 162 , the fluid 170 in the electrode connector 140 , the infusion electrode 80 , the electrode port 142 , and the second terminal 47 of the power supply 46 .
  • Other pathways completing a circuit can include other components or regions.
  • an infusion fluid 170 can be provided from the fluid source 150 to the infusion port 60 , shown in FIGS. 5 and 6 , to provide fluid communication to the distal end 112 of the delivery catheter 100 .
  • the fluid can be biocompatible and generally conductive. Infusion may be accomplished by the pump 160 or other flow-inducing device.
  • the infusion port 60 can be provided in fluid communication with and electrical connection with a distal end 112 of the delivery catheter 100 .
  • the infusion electrode 80 may be integrated with the body of the delivery catheter 100 such that the infusion electrode 80 extends distally within the sidewall 190 of the delivery catheter 100 rather than within the lumen 124 of the delivery catheter 100 .
  • the infusion electrode 80 may extend distally from the proximal end 110 of the delivery catheter 100 to a transmission portion adjacent the detachment zone 30 .
  • At least a region of the transmission portion may be exposed to the lumen 124 such that, when fluid 170 flows through the lumen 124 and the power supply 46 is providing a voltage across the first and second terminals 48 , 47 , an electrical current passes through the first terminal 48 of the power supply 46 , the delivery electrode 82 , the proximal region 31 of the delivery wire 44 , the detachment zone 30 , the fluid 170 in the lumen 124 of the delivery catheter 100 , the transmission portion, the infusion electrode 80 , and the second terminal 47 of the power supply 46 .
  • the exposed region of the transmission portion is located along the length of the delivery catheter 100 within 2 inches of the detachment zone 30 . In some embodiments, the exposed region of the transmission portion is located along the length of the delivery catheter 100 within 1-2 inches of the detachment zone 30 . In some embodiments, the exposed region of the transmission portion is located along the length of the delivery catheter 100 within 1 inch of the detachment zone 30 .
  • the transmission portion and the infusion electrode 80 are a single, continuous component or material (e.g., integral with one another), and the transmission portion may be a portion of the infusion electrode 80 that is exposed to the lumen 124 .
  • the infusion electrode 80 may be an elongated, conductive member (e.g., a wire) that is insulated within the sidewall 190 of the delivery catheter 100 , and the transmission portion is a portion of the conductive member that is exposed to the lumen 124 through the sidewall 190 within 2 inches of the detachment zone 30 .
  • the sidewall 190 of the delivery catheter 100 includes a coil and/or braid along its length that include one or more conductive materials.
  • a proximal end portion of the coil and/or braid can be electrically coupled to the second terminal 47 of the power source (directly or indirectly via one or more connectors) and a distal end portion of the braid and/or coil may be exposed through the sidewall 190 to the lumen 124 within 2 inches of the detachment zone.
  • a distal end portion of the braid and/or coil may be exposed through the sidewall 190 to the lumen 124 within 1-2 inches of the detachment zone, and in some embodiments within 1 inch of the detachment zone.
  • the transmission portion may be the exposed length of the coil and/or braid
  • the infusion electrode 80 may be the length of the coil and/or braid between the second terminal 47 and the exposed portion.
  • the transmission portion and the infusion electrode 80 are separate components that are electrically coupled to one another.
  • the infusion electrode 80 may be a first conductive element (e.g., a wire, a braid, a coil, etc.) that is insulated within the sidewall 190 of the delivery catheter 100
  • the transmission portion is a second conductive element (e.g., all or part of a marker band, a braid, a coil, etc.) having at least a region exposed to the lumen 124 through the sidewall 190 within 2 inches of the detachment zone 30 .
  • the second conductive element has at least a region exposed to the lumen 124 through the sidewall 190 within 1-2 inches of the detachment zone 30 , and in some embodiments within 1 inch of the detachment zone.
  • a distal end portion of the infusion electrode 80 may be electrically coupled to a proximal end portion of the transmission portion.
  • FIGS. 7-9 illustrate various stages of an exemplifying method according to one or more embodiments of the subject technology.
  • FIG. 7 illustrates an implant 20 inserted within the aneurysm 2 .
  • FIG. 8 illustrates a stage of detachment in progress
  • FIG. 9 illustrates a stage following detachment of the implant 20 from the pusher assembly 12 .
  • the delivery catheter 100 is advanced to place its distal end 112 in the vicinity of a target site (e.g., an aneurysm 2 ).
  • a target site e.g., an aneurysm 2
  • other components and stages may also be employed.
  • the delivery catheter 100 may be guided to the target site by a guide wire and/or a guide catheter, according to known techniques.
  • the implant 20 can be advanced over a guidewire (not shown) through the lumen 124 to the target site.
  • the implant 20 can be placed within the aneurysm and deployed.
  • the implant 20 is advanced from the delivery catheter 100 to the target site.
  • the implant 20 may be placed at the target site, and the delivery catheter 100 may be subsequently advanced or retracted relative to the pusher assembly 12 while the pusher assembly 12 holds the implant 20 steady.
  • the delivery catheter 100 may be positioned such that the detachment zone is entirely exposed, partially exposed, or not exposed by the delivery catheter 100 .
  • the detachment zone 30 may be distal to, overlapping with, or proximal to the distal end 112 of the delivery catheter 100 .
  • the detachment zone 30 can be longitudinally aligned with the distal end of the delivery catheter 100 .
  • Positioning of the delivery catheter 100 relative to the pusher assembly 12 (e.g., relative to the detachment zone 30 ) and/or implant 20 may be facilitated by components providing visualization.
  • a radiopaque marker of the delivery catheter 100 can be longitudinally aligned with a radiopaque marker of the pusher assembly 12 and/or the implant 20 to provide confirmation that the implant 20 is positioned outside of the delivery catheter 100 .
  • electrolytic detachment of the implant 20 from the pusher assembly 12 can be achieved.
  • One or both of the detachment zone 30 and the infusion electrode 80 can be energized to apply electrical energy.
  • the detachment zone 30 and the infusion electrode 80 can be energized with electrical energy of opposite polarity to create a voltage potential and pass electrical current through the fluid 170 between the detachment zone 30 and the infusion electrode 80 . While the electrical current can pass predominantly through the fluid 170 , current induced by the voltage potential may also pass along other pathways. Fluids other than the fluid 170 from the fluid source 150 can contribute to an electrical pathway. For example, blood from the body of the patient may mix with the fluid 170 and form a portion of the pathway.
  • a current source e.g., the power supply 46
  • a current source connected to the infusion electrode 80 is activated. While one of the detachment zone 30 and the infusion electrode 80 are energized, the other can be energized with an opposite polarity or grounded.
  • the detachment zone 30 and the infusion electrode 80 can each be multifunctional. For example, each can serve as either an active electrode or a ground electrode at different points in time as the treatment proceeds. By further example, each can serve as either a cathode or an anode at different points in time as the treatment proceeds. If desired, during the period of time that a voltage potential is formed, the polarity can be switched once or repeatedly, to create currents traveling in either direction across the gap between the detachment zone 30 and the infusion electrode 80 .
  • fluid flow 170 can be provided during electrolytic detachment of the implant 20 from the pusher assembly 12 .
  • an infusion of fluid from the fluid source 150 by the pump 160 can be provided via the delivery catheter 100 past the detachment zone 30 .
  • the fluid flow 170 can be directed distally from the lumen 124 to a region distal to the distal end 112 of the delivery catheter 100 .
  • the fluid flow 170 can be directed proximally into the lumen 124 from a region distal to the distal end 112 of the delivery catheter 100 .
  • the fluid flow 170 may evacuate any bubbles that form near the detachment zone 30 .
  • the formation of bubbles can also change the dielectric characteristics of the vicinity of the detachment zone 30 .
  • bubbles can serve as a dielectric material and electrically insulate the detachment zone 30 from the infusion electrode 80 .
  • Such a condition can create a dielectric region with an undesirably high breakdown voltage.
  • the fluid flow 170 can refresh the fluid composition within the gap to maintain a clear conduction path.
  • the fluid flow 170 may evacuate debris from the vicinity of the detachment zone 30 .
  • the debris can form or facilitate a short circuit from the detachment zone 30 to other structures, thereby creating a conductive bridge and reducing the rate of electrolytic detachment of the detachment zone 30 .
  • the fluid flow 170 can remove the debris to maintain a clear pathway for electrical current between the detachment zone 30 and the infusion electrode 80 .
  • the fluid flow 170 can be provided during part or all of an electrolytic detachment operation.
  • the fluid flow 170 may commence before, during, or after initial application of a voltage potential between the detachment zone 30 and the delivery catheter 100 .
  • the fluid flow 170 may cease before, during, or after termination of the voltage potential.
  • the fluid flow 170 can be provided intermittently based on conditions existing during the electrolytic detachment process.
  • the fluid flow 170 can be provided when and/or only when the power supply 46 outputs a voltage and/or current above and/or below a threshold.
  • a controller of the power supply 46 detects an increase (e.g., short circuit) or decrease (e.g. open circuit) of current flow between the detachment zone 30 and the infusion electrode 80
  • the fluid flow 170 can be controllably provided until the current flow normalizes to a desired value or range of values, representative of efficient electrolytic corrosion.
  • the flow of fluid can be continuous throughout a stage or an entirety of a process.
  • the flow can have an increased rate during portions of a process to remove debris and reduce thrombus formation.
  • full corrosion of the detachment zone 30 results in the implant 20 being entirely separated from the pusher assembly 12 .
  • the fluid flow 170 can cease, and the pusher assembly 12 and the delivery catheter 100 can be retracted away from the target site and out of the patient, leaving the implant 20 at the target site.
  • Embodiments disclosed herein can be used in veterinary or human medicine and more particularly, for the endovascular treatment of intracranial aneurysms and acquired or innate arteriovenous blood vessel deformities and/or fistulas and/or for the embolization of tumors.
  • vessels can include arteries or veins.
  • the vessels can be suprathoracic vessels (e.g., vessels in the neck or above), intrathoracic vessels (e.g., vessels in the thorax), subthoracic vessels (e.g., vessels in the abdominal area or below), lateral thoracic vessels (e.g., vessels to the sides of the thorax such as vessels in the shoulder area and beyond), or other types of vessels and/or branches thereof.
  • the stent delivery systems disclosed herein can be deployed within superthoracic vessels.
  • the suprathoracic vessels can include at least one of intracranial vessels, cerebral arteries, and/or any branches thereof.
  • the stent delivery systems disclosed herein can be deployed within intrathoracic vessels.
  • the intrathoracic vessels can include the aorta or branches thereof.
  • the stent delivery systems disclosed herein can be deployed within subthoracic vessels.
  • the stent delivery systems disclosed herein can be deployed within lateral thoracic vessels.
  • a phrase such as “an aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology.
  • a disclosure relating to an aspect may apply to all configurations, or one or more configurations.
  • An aspect may provide one or more examples of the disclosure.
  • a phrase such as “an aspect” may refer to one or more aspects and vice versa.
  • a phrase such as “an embodiment” does not imply that such embodiment is essential to the subject technology or that such embodiment applies to all configurations of the subject technology.
  • a disclosure relating to an embodiment may apply to all embodiments, or one or more embodiments.
  • An embodiment may provide one or more examples of the disclosure.
  • a phrase such “an embodiment” may refer to one or more embodiments and vice versa.
  • a phrase such as “a configuration” does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology.
  • a disclosure relating to a configuration may apply to all configurations, or one or more configurations.
  • a configuration may provide one or more examples of the disclosure.
  • a phrase such as “a configuration” may refer to one or more configurations and vice versa.

Abstract

Detachment of an implant from a delivery assembly can be electrolytic and provide an electrical current pathway through a fluid within a portion of a delivery system containing the delivery assembly. After the implant is located at a target location within a patient, a voltage potential is applied between (i) a delivery electrode electrically connected to an electrolytic detachment zone and (ii) an infusion electrode disposed outside of the patient and electrically connected to the electrolytic detachment zone via a fluid from a fluid source disposed outside of the patient. While applying the voltage potential, the fluid can be flushed from the fluid source past the detachment zone.

Description

    RELATED APPLICATIONS
  • This application is a divisional of U.S. application Ser. No. 15/619,774, filed Jun. 12, 2017, which claims priority to provisionally filed U.S. Patent Application No. 62/354,939, filed Jun. 27, 2016, both of which are incorporated herein by reference in their entirety.
  • TECHNICAL FIELD
  • The subject technology relates to the delivery of implantable medical devices and systems for delivering implantable medical devices.
  • BACKGROUND
  • The use of endovascular techniques for the implantation of medical devices for the treatment and the occlusion of body cavities such as arteries, veins, fallopian tubes or vascular deformities is known in the art. For example, vascular aneurysms can be occluded with an implantable medical device that is introduced to the vasculature with a delivery wire through a catheter. Once advanced to the treatment site, the medical device can be inserted into the aneurysm cavity to occlude the aneurysm and then detached from the delivery wire.
  • SUMMARY
  • Detachment of a medical device or implant from the delivery wire can be problematic. It is essential that the implant can be collapsed to form as small a profile as possible to be guided through the fine bore of the catheter, and it must bring about a reliable severance of the implant from the wire. Absent a reliable severance of the implant, withdrawal of the delivery wire and catheter may cause unintended removal of the implant from the aneurysm, and thus injure and/or rupture of the wall of the aneurysm or vessel.
  • While some mechanical methods for the detachment of implants are reliable, the rigidity of the connection between the implant and the delivery means necessary for such methods can impede the introduction of the implant. Furthermore, the low load carrying capacity of the connection (due to its rigidity) entails an appreciable risk of premature detachment of the insertion means from the occluding implant. Moreover, in the case of mechanical separation of the delivery wire and the implant, mechanical energy must be transmitted (e.g., by rotation of the delivery wire), which may cause the implant to be dislodged out of the correct position.
  • Electrolytic detachment of an implantable medical device can involve using an electrolytically corrodible region on the end of a delivery wire at the connection between the delivery wire and the medical device. Known methods of electrolytic detachment can employ an electrolytically corrodible region on the end of the delivery wire at the connection between the delivery wire and the implant. However, the connection of the implant to the delivery wire is limited by the requirements of the electrolytically corrodible region. For example, only materials that have a sufficiently high degree of strength to enable reliable guidance of the implant can be utilized in delivery wire material selection.
  • Additional features and advantages of the subject technology will be set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and claims hereof as well as the appended drawings.
  • The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause (1 and 16). The other clauses can be presented in a similar manner.
  • 1. A delivery system comprising:
      • a catheter having a proximal end region, a distal end region, and a lumen extending from the proximal end region to the distal end region along a length that facilitates access from an entry region outside of a patient to a target location within the patient;
      • a delivery wire extending through at least a portion of the lumen;
      • an implant attached to the delivery wire by an electrolytically corrodible detachment zone;
      • a fluid source disposed outside of the lumen and in fluid communication with the distal end region via the proximal end region and the lumen;
      • a delivery electrode contacting the delivery wire and electrically connected to the electrolytically corrodible detachment zone via the delivery wire; and
      • an infusion electrode contacting fluid within the lumen, the infusion electrode electrically connected to the electrolytically corrodible detachment zone via the fluid within the lumen.
  • 2. The delivery system of example 1, further comprising a pump configured to provide a flow of the fluid within the lumen to the detachment zone.
  • 3. The delivery system of example 1 or example 2, further comprising a power supply connected to the delivery electrode and the infusion electrode.
  • 4. The delivery system of example 3, wherein the power supply is configured to provide a voltage potential between the delivery electrode and the infusion electrode.
  • 5. The delivery system of any one of examples 1-4, wherein at least a portion of the outer surface of the delivery wire is electrically insulated.
  • 6. The delivery system of any one of examples 1-5, wherein the delivery electrode contacts the delivery wire at the entry region outside the patient.
  • 7. The delivery system of any one of examples 1-6, wherein the infusion electrode contacts the fluid at the entry region outside the patient.
  • 8. The delivery system of any one of examples 1-7, further comprising an electrode interface connected to the proximal end region and configured to receive at least a portion of the infusion electrode to a space containing the fluid.
  • 9. The delivery system of any one of examples 1-8, wherein the detachment zone is of a material that is more susceptible to electrolytic corrosion than a material of the delivery wire or a material of the implant.
  • 10. The delivery system of any one of examples 1-9, wherein the fluid comprises saline.
  • 11. The delivery system of any one of examples 1-10, wherein a distal tip of the infusion electrode is positioned within the lumen within 2 inches of the detachment zone.
  • 12. The delivery system of any one of examples 1-11, wherein a distal tip of the infusion electrode is positioned within the lumen within 1 inch of the detachment zone.
  • 13. The delivery system of any one of examples 1-10, wherein the infusion electrode extends within the sidewall from the proximal end region of the catheter to the distal end region of the catheter.
  • 14. The delivery system of example 13, wherein a portion of the infusion electrode is exposed through the sidewall within 2 inches of the detachment zone.
  • 15. The delivery system of example 13, wherein a portion of the infusion electrode is exposed through the sidewall within 1 inch of the detachment zone.
  • 16. A method of delivering an implant, the method comprising:
      • positioning the implant at a target location within a patient, the implant being attached to a delivery wire by an electrolytically corrodible detachment zone;
      • applying a voltage potential between (i) a delivery electrode electrically connected to the electrolytically corrodible detachment zone via the delivery wire and (ii) an infusion electrode disposed outside of the patient and electrically connected to the electrolytically corrodible detachment zone via a fluid from a fluid source disposed outside of the patient; and
      • while applying the voltage potential, flushing the fluid from the fluid source past the electrolytically corrodible detachment zone.
  • 17. The method of example 16, wherein positioning the implant comprises:
      • positioning a catheter with a proximal end region outside the patient and a distal end region at the target location; and
      • advancing the implant through a lumen of the catheter.
  • 18. The method of example 17, wherein applying the voltage potential comprises:
      • connecting the delivery electrode to a portion of the delivery wire disposed outside of the patient; and
      • connecting the infusion electrode to a portion of the catheter disposed outside of the patient.
  • 19. The method of any one of examples 16-18, wherein applying the voltage potential comprises applying a voltage potential between the delivery electrode and the infusion electrode.
  • 20. The method of any one of examples 16-19, wherein applying the voltage potential comprises:
      • connecting the delivery electrode to a portion of the delivery wire disposed outside of the patient; and
      • connecting the infusion electrode to a portion of the fluid source disposed outside of the patient.
  • 21. The method of any one of examples 16-20, wherein applying the voltage potential comprises applying the voltage potential until the detachment zone has corroded.
  • 22. The method of any one of examples 16-21, wherein the voltage potential is applied until the implant is separated from the delivery wire.
  • 23. The method of any one of examples 16-22, wherein the fluid is flushed until the implant is separated from the delivery wire.
  • 24. The method of any one of examples 16-23, wherein at least a portion of an outer surface of the delivery wire is electrically insulated.
  • 25. The method of any one of example 16-24, wherein the fluid comprises saline.
  • 26. The method of any one of examples 16-25, wherein positioning the implant at a target location is through a lumen of a catheter, and wherein a distal tip of the infusion electrode is positioned within the lumen within 2 inches of the detachment zone.
  • 27. The method of any one of examples 16-26, wherein positioning the implant at a target location is through a lumen of a catheter, and wherein a distal tip of the infusion electrode is positioned within the lumen within 1 inch of the detachment zone.
  • 28. The method of any one of examples 16-25, wherein the infusion electrode extends within the sidewall from the proximal end region of the catheter to the distal end region of the catheter.
  • 29. The method of example 28, wherein a portion of the infusion electrode is exposed through the sidewall within 2 inches of the detachment zone.
  • 30. The method of example 28, wherein a portion of the infusion electrode is exposed through the sidewall within 1 inch of the detachment zone.
  • It is to be understood that both the foregoing general description and the following detailed description are exemplifying and explanatory and are intended to provide further explanation of the subject technology as claimed.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying drawings, which are included to provide further understanding of the subject technology and are incorporated in and constitute a part of this description, illustrate aspects of the subject technology and, together with the specification, serve to explain principles of the subject technology.
  • FIG. 1 shows a perspective view of a delivery system having an electrical return path, in accordance with one or more embodiments of the present disclosure.
  • FIG. 2 shows a perspective side view of a braid ball implant, in accordance with one or more embodiments of the present disclosure.
  • FIG. 3 shows a side-sectional view of the braid ball implant of FIG. 2 deployed within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • FIG. 4 shows a sectional view of a distal end of the delivery system of FIG. 1, in accordance with one or more embodiments of the present disclosure.
  • FIG. 5 shows a side view of the delivery system of FIG. 1, in accordance with one or more embodiments of the present disclosure.
  • FIG. 6 shows a sectional view of the delivery system of FIGS. 1 and 5, in accordance with one or more embodiments of the present disclosure.
  • FIG. 7 shows a partial sectional view of an implant detachment zone at a stage of implant deployment within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • FIG. 8 shows a partial sectional view of an implant detachment zone at a stage of implant deployment within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • FIG. 9 shows a partial sectional view of an implant detachment zone at a stage of implant deployment within a bifurcation aneurysm, in accordance with one or more embodiments of the present disclosure.
  • DETAILED DESCRIPTION
  • In the following detailed description, specific details are set forth to provide an understanding of the subject technology. It will be apparent, however, to one ordinarily skilled in the art that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and techniques have not been shown in detail so as not to obscure the subject technology.
  • Implants can be implanted in body cavities, including blood vessels. Implants can be delivered to a target body cavity using a delivery system, and detached from the delivery system when positioned within the body cavity. A delivery system can comprise a delivery wire having an electrolytically corrodible detachment zone between the implant and the delivery system. When a voltage potential is applied across the detachment zone while in an electrolyte, such as blood for example, the detachment zone corrodes. When sufficiently corroded, the detachment zone is severed, releasing the implant from the delivery system.
  • In some delivery systems, the voltage potential can be generated using a power supply electrically connected to the delivery system. The power supply or ground can be electrically connected to a patient on the surface of the patient's skin to provide a conductive pathway from a detachment zone at or near the implant. The conductive pathway can require a secure connection, such as with a transcutaneous needle or other device that punctures the patient. The current would then flow through the patient and the needle between the detachment zone and the ground or power supply.
  • Whereas some systems require a needle puncturing the patient to complete a conductive pathway, an electrical connection to a detachment zone can be achieved without puncturing the patient. According to one or more aspects of the subject technology, electrolytic detachment can be facilitated by a closed circuit of electrical current entirely within a delivery system, thereby avoiding the need to insert a needle into the patient to complete a circuit through the patient's tissue. Thus, patient comfort is improved and resistance within the circuit is reduced, thereby improving detachment time and reliability.
  • FIG. 1 illustrates a view of a delivery system 10 according to one or more embodiments of the subject technology. According to some embodiments, for example, as shown in FIG. 1, the delivery system 10 can include an implant 20, a pusher assembly 12, and a delivery catheter 100 connected to a handle 42. The handle 42 shown provides proximal access to a delivery wire 44 of the pusher assembly 12 that engages the implant 20 at a distal end thereof. The delivery wire 44 can be connected to the implant at a detachment zone 30 forming a detachment junction between the delivery wire 44 and the implant 20 at or near the implant 20. The delivery catheter 100 can be positioned over the pusher assembly 12. According to some embodiments, the power supply 46 can be coupled to a proximal portion of the delivery wire 44, and the power supply 46 also can be coupled (e.g., to the handle 42) such that one of the terminals of the power supply 46 is in electrical connection with a fluid and/or fluid flow 170 in a vicinity of the implant 20, as described further herein.
  • According to some embodiments, the power supply 46 can include an electrical generator configured to output medically useful electrical current. The power supply 46 may be a direct current power supply, an alternating current power supply, or a power supply switchable between a direct current and an alternating current. The power supply 46 can include a suitable controller that can be used to control various parameters of the energy output by the generator, such as intensity, amplitude, duration, frequency, duty cycle, and polarity. For example, the power supply 46 can provide a voltage of about 12 volts to about 28 volts and a current of about 1 mA to about 2 mA.
  • According to some embodiments, for example as shown in FIG. 1, a fluid source 150 may be provided in fluid connection with a pump 160 for infusion of the fluid via the delivery catheter 100. The fluid source 150 can include saline or another sterile, electrolytic, biocompatible solution. The fluid can be infused together with a drug, such as heparin. The pump can draw fluid from the fluid source 150 and advance the fluid into and through a lumen 124 (FIG. 6) of the delivery catheter 100. The pump 160 can be an infusion pump, a syringe, a compressor, a pressurized container, and/or a gravity-based infusion mechanism.
  • According to some embodiments, for example as shown in FIGS. 2 and 3, an implant 20 delivered by the delivery system 10 can be a braid ball implant. The implant 20 can be formed from tubular braid stock including a resilient material, such as nitinol, that defines an open volume in an uncompressed/unconstrained state. The size of the implant can be selected to fill an aneurysm 2 when expanded therein. The implant 20 can include a hub 50 and layers 26, 28. The hub can be located at a proximal end 53 of the implant. The hub 50 can be fixedly attached to the remainder of the implant 20. For example, the hub 50 can grasp braided filaments of the layers 26, 28 of the implant 20. The implant 20 can include the layers 26, 28 at least where impacted by flow at the neck 9 of the aneurysm 2.
  • While the implant 20 illustrated herein is a braided ball, the implant 20 can be any well-known treatment device including, but not limited to, vasoocclusive coils, stents, filters, or flow diverters.
  • According to some embodiments, the implant 20 can be set within an aneurysm 2 at a vascular bifurcation 4, formed by trunk vessel 6 and branch vessels 8, for example as illustrated in FIG. 3. The implant 20 can be delivered by access through the trunk vessel 6 (e.g., the basilar artery), preferably through a commercially available microcatheter with a delivery system as detailed below. To deliver the implant 20, the pusher assembly 12 is positioned such that the implant 20 can be delivered at least partially into the aneurysm 2. When the implant is positioned in the aneurysm, the implant 20 is separated from the remainder of the pusher assembly 12 by electrolytic corrosion at the detachment zone 30, and the remainder of the pusher assembly 12 is withdrawn into the delivery catheter 100.
  • FIG. 4 illustrates a sectional view of a pusher assembly 12 according to one or more embodiments of the subject technology. According to some embodiments, for example as shown in FIG. 4, a pusher assembly 12 includes a delivery wire 44 having a proximal region 31, a distal region 33, and a detachment zone 30 between the proximal region 31 and the distal region 33. The delivery wire 44 can form a single, monolith component across the proximal region 31, the distal region 33, and the detachment zone 30, or the delivery wire 44 can be formed of separate segments joined together.
  • According to some embodiments, portions of the delivery wire 44 can be coated with a nonconductive material so that only a limited portion of surface area of the delivery wire is exposed to, and in electrical communication with, the electrolyte for corrosion when a voltage potential is applied. Limiting the size of the exposed portion of the surface area of the delivery wire can concentrate electrolytic activity to expedite corrosion through and severance of the delivery wire. A proximal insulating layer 34 can be provided over at least a portion of an outer surface of the proximal region 31. For example, the proximal insulating layer 34 can circumferentially surround an outer surface of the proximal region 31 extending proximally from a proximal end of the detachment zone 30 to a location at or near a proximal end of the delivery wire 44. According to some embodiments, a distal insulating layer 32 can be provided over at least a portion of an outer surface of the distal region 33 extending distally from a distal end of the detachment zone 30 to a distal terminal end of the delivery wire 44. For example, the distal insulating layer 32 can circumferentially surround and cover the entire outer surface of the distal region 33.
  • According to some embodiments, proximal and distal insulating layers 34, 32 leave exposed the portion of the delivery wire 44 forming the detachment zone 30 between the proximal region 31 and the distal region 33. When in contact with a body fluid, such as blood, the fluid serves as an electrolyte allowing current to be focused on the non-coated detachment zone 30. The proximal and distal insulating layers 34, 32 prevent exposure of the proximal region 31 and the distal region 33 to the fluid. Accordingly, electrical energy conducted along the delivery wire 44 is concentrated at the detachment zone 30, thereby reducing the time required to erode away the detachment zone 30. The proximal and distal insulating layers 34, 32 can be over-molded, co-extruded, sprayed on, or dip-coated with respect to the proximal region 31 and/or the distal region 33.
  • The distal insulating layer 32 also prevents electrical connection between the delivery wire 44 and the implant. As shown in FIG. 4, the distal insulating layer 32 electrically isolates the implant 20 from an electrical current conducted along a length of the delivery wire, from the proximal region 31 to the distal region 33. A proximal end of the distal insulating layer 32 may be positioned at or proximal to the hub 50, and a distal end of the distal insulating layer 32 may be positioned at or distal to the hub 50 Likewise, a proximal end of the distal region 33 may be positioned proximal to the hub 50, and a distal end of the distal region 33 may be positioned within or distal to the hub 50. The distal insulating layer 32 insulates the distal region 33 from the hub 50 to prevent the electrical current from being conducted to the implant 20.
  • The proximal and distal insulating layers 34, 32 can comprise an electrically nonconductive or insulative polymer, such as polyimide, polypropylene, polyolefins, or combinations thereof. In some embodiments, the proximal and distal insulating layers 34, 32 can be applied as a single coating with a portion thereof subsequently removed to expose the detachment zone 30. Laser ablation can be employed to selectively remove the coating to a controlled length, minimizing the time required to erode through the component. Lengths as small as 0.0005″ and as large as 0.1″ or longer can be removed. According to some embodiments, lengths of detachment zone 30 can be greater than 0.005″ and/or less than 0.010″ to provide sufficient exposure to achieve detachment times of less than 30 seconds.
  • The delivery wire 44 (including some or all of the proximal region 31, the distal region 33, or the detachment zone 30) can comprise one or more of the following materials: ceramic materials, plastics, base metals or alloys thereof, or combinations thereof. Some of the most suitable material combinations for forming the electrolytically corrodible points can include one or more of the following: stainless steels, preferably of the type AISI 301, 304, 316, or subgroups thereof; Ti or TiNi alloys; Co-based alloys; noble metals; or noble metal alloys, such as Pt, Pt metals, Pt alloys, Au alloys, or Sn alloys. In some embodiments, the electrolytically corrodible detachment zone can be pre-corroded by etching or other methods. According to some embodiments, a marker coil 36 is wound helically about an outer surface of the proximal insulating layer 34. The marker coil 36 can be of a radiopaque material, such as platinum, gold, palladium, iridium, and alloys thereof. The proximal insulating layer 34 can be provided about an outer surface of the marker coil 36. For example, as shown in FIG. 4, the proximal insulating layer 34 can extend over an entire length of the marker coil 36 and distally beyond the marker coil 36, such that every portion of the marker coil 36 is covered by the proximal insulating layer 34.
  • According to some embodiments, for example as shown in FIG. 4, the delivery wire 44 can be continuous through the proximal region 31. Accordingly, an electric potential applied to the proximal end of the delivery wire 44 can induce an electrical current conducted through the delivery wire 44 along the proximal region 31 to the detachment zone 30. Furthermore, an axial force applied to the delivery wire 44 can result in an axial movement of the detachment zone 30 and the implant 20.
  • FIGS. 5 and 6 illustrate various views of a delivery system 10 according to some embodiments of the subject technology. FIG. 5 depicts a side view of a delivery system 10 and FIG. 6 depicts a sectional view of the delivery system 10 as shown in FIG. 5. The delivery system 10 illustrated in FIGS. 5 and 6 is similar in some respects to the delivery system 10 of FIG. 1 and can be understood with reference thereto, where like numerals indicate like elements or components not described again in detail. FIGS. 5 and 6 illustrate electrical connection of a power supply 46 to a delivery wire 44 and a fluid and/or fluid flow 170 in a vicinity of the detachment zone 30 of the delivery wire 44. An electrical pathway can pass from a first terminal 48 of the power supply to the delivery wire 44 and into a fluid/fluid flow 170 at the detachment zone 30, and then return to a second terminal 47 of the power supply 46 through the fluid/fluid flow.
  • According to some embodiments, for example as shown in FIGS. 5 and 6, the delivery catheter 100 can be formed as a generally tubular member with a body extending from a proximal end 110 and terminating in a distal end 112. An inner lumen 124 extends from a proximal port 45 of the delivery catheter 100. The delivery catheter 100 can generally track over a conventional guidewire and may be any commercially available microcatheter appropriate for such applications. Inner lumen 124 of the delivery catheter generally has an inner diameter between about 0.01 inch and about 0.098 inch (0.25-2.49 mm). Other designs and dimensions are contemplated. Commercially available microcatheters which may be suitable for use as delivery catheters include the REBAR™ Reinforced Micro Catheter, which is available from Medtronic, Inc. and the MARKSMAN™ Catheter, which is available from Medtronic, Inc.
  • According to some embodiments, the proximal port 45 of the delivery catheter 100 may be provided with an adapter (not shown) having a hemostatic valve. The proximal port 45 may comprise a valve or other sealable mechanism for receiving at least a portion of the pusher assembly 12 while preventing passage of the fluid flow 170 proximally past the proximal port 45 in the presence or absence of the delivery wire 44. For example, the proximal port 45 can include a split septum, slit valve, duckbill valve, dome valve, donut valve, multi-cuspid valve, or combinations thereof. The proximal port 45 can include a hydrophobic coating.
  • The delivery catheter 100 is generally constructed to bridge between a femoral artery access site and a cervical region of the carotid or vertebral artery and may be chosen according to several standard designs that are generally available. Accordingly, the delivery catheter 100 may be at least 85 cm long, and more particularly may be between about 95 cm and about 175 cm long. For example, a distance between (a) the proximal port 45 and/or the infusion port 60 (FIG. 5) and (b) the distal end 112 can be at least 85 cm, and more particularly may be between about 95 cm and about 175 cm long.
  • According to some embodiments, at least a portion of the delivery wire 44 extends through the proximal port 45 at the proximal end 110 of the delivery catheter 100. A delivery electrode 82 is configured to be coupled to the delivery wire 44. A variety of coupling mechanisms may be employed to selectively secure the delivery electrode 82 to the delivery wire 44 such that an electrical connection is established. For example, the delivery electrode 82 can include a clamp, pin, ring, clasp, or combinations thereof to engage a complementary structure of the delivery wire 44. The delivery electrode 82 is further configured to be coupled to the first terminal 48 (e.g., cathode or anode) of the power supply 46. An electrical potential generated at the first terminal 48 can induce an electrical current through the delivery electrode 82 and the delivery wire 44 to the detachment zone 30. Flow of electrical current between the delivery wire and the immediately surrounding environment (e.g., the fluid and/or fluid flow 170) can be focused at the detachment zone 30 by insulating a length of the delivery wire 44 with the proximal insulating layer 34 at least from the proximal port 45 to the detachment zone 30. At least a portion of the proximal insulating layer 34 may extend to the proximal port 45 and/or proximally thereof to insulate the delivery wire 44 from the fluid flow 170 within the lumen 124 of the delivery catheter 100.
  • According to some embodiments, an infusion connector 62 can provide a connection to the infusion port 60 for infusion of fluid and electrical connections. The infusion connector 62 can connect to an interface with the infusion port 60 on a first end. The infusion connector 62 can further provide an electrode connector 140 and a fluid connector 162. The infusion connector 62 can define a lumen that divides and connects to both an electrode port 142 of the electrode connector 140 and the pump 160 and fluid source 150 of the fluid connector 162.
  • The entirety or a portion of the infusion connector 62 and components thereof can be located outside a body of the patient. For example, the fluid connector 162, the electrode connector 140, the electrode port 142, the pump 160, and/or the fluid source 150 can be located outside a body of the patient during use. Further, components interfacing with the infusion connector 62 and components thereof can be located outside a body of the patient.
  • The infusion connector 62 can take the form of a Y-connector. Additional connectors can be provided in addition to the electrode connector 140 and the fluid connector 162. The interior lumens of the infusion connector 62 provide fluid communication and electrical connection through the fluid and between the infusion port 60, the electrode port 142, and the fluid source 150. Through the fluid 170 and the infusion port 60, the components of the infusion connector 62 can be placed in fluid communication and electrical connection with the lumen 124 of the delivery catheter 100, as well as components residing in and near the lumen 124, including the detachment zone 30.
  • According to some embodiments, the electrode connector 140 is configured to receive an infusion electrode 80. In some embodiments, at least a portion of the infusion electrode 80 extends distally through the electrode port 142 and at least a portion of the lumen of the electrode connector 140. In some embodiments, such as that shown in FIGS. 5 and 6, the infusion electrode 80 extends through the electrode connector 140 and into the lumen of the infusion connector 62. In some embodiments, the infusion electrode 80 may extend through the infusion connector 62 and through the infusion port 60. In some embodiments the infusion electrode 80 may extend into the lumen 124 of the delivery catheter 100 such that the distal tip of the infusion electrode 80 terminates within the lumen 124. In some embodiments, the infusion electrode 80 extends distally along the length of the delivery catheter 100 within the lumen 124 such that the distal tip of the infusion electrode 80 terminates within 2 inches of the detachment zone 30, and in some embodiments within 1 inch of the detachment zone 30. In any of the foregoing embodiments, at least a portion of the infusion electrode 80 between the second terminal 47 and a region adjacent the detachment zone 30 may be electrically insulated so long as the portion of the infusion electrode 80 within 2 inches of the detachment zone 30 is exposed (e.g., in electrical communication with the fluid pathway).
  • The infusion electrode 80 is configured to pass through the electrode port 142 to contact and/or be in electrical connection with the fluid 170 within the infusion connector 62 and/or the delivery catheter 100. For example, the infusion electrode 80 can comprise a needle or other elongate member. The electrode port 142 may comprise a valve or other sealable mechanism for receiving at least a portion of the infusion electrode 80 while preventing passage of the fluid flow 170 proximally past the electrode port 142 in the presence or absence of the infusion electrode 80. For example, the electrode port 142 can include a split septum, slit valve, duckbill valve, dome valve, donut valve, multi-cuspid valve, or combinations thereof. The electrode port 142 can include a hydrophobic coating. Alternatively or in combination, the infusion electrode 80 can be placed in electrical connection with the fluid 170 without directly contacting the fluid 170. For example, the infusion electrode 80 can include a clamp, pin, ring, clasp, or combinations thereof to engage the electrode port 142, thereby placing the infusion electrode 80 in electrical connection with the fluid 170.
  • The infusion electrode 80 is further configured to be coupled to the second terminal 47 (e.g., cathode or anode) of the power supply 46. An electrical potential generated at the second terminal 47 can induce an electrical current through the infusion electrode 80 and the fluid 170 (e.g., along the lumen 124) to the vicinity of the detachment zone 30. The infusion electrode 80 can be a “painted” electrode on a surface of a non-conductive material. The infusion electrode 80 can include platinum, platinum alloys (e.g., 92% platinum and 8% tungsten, 90% platinum and 10% iridium), gold, cobalt-chrome, stainless steel (e.g., 304 or 316), and combinations thereof.
  • According to some embodiments, an electrical pathway can pass through one or more of the first terminal 48 of the power supply 46, the delivery electrode 82, the proximal region 31 of the delivery wire 44, the detachment zone 30, the fluid 170 in the lumen 124 of the delivery catheter 100, the fluid 170 in the infusion port 60, the fluid 170 in the fluid connector 162, the fluid 170 in the electrode connector 140, the infusion electrode 80, the electrode port 142, and the second terminal 47 of the power supply 46. Other pathways completing a circuit can include other components or regions.
  • According to some embodiments, an infusion fluid 170 can be provided from the fluid source 150 to the infusion port 60, shown in FIGS. 5 and 6, to provide fluid communication to the distal end 112 of the delivery catheter 100. The fluid can be biocompatible and generally conductive. Infusion may be accomplished by the pump 160 or other flow-inducing device. The infusion port 60 can be provided in fluid communication with and electrical connection with a distal end 112 of the delivery catheter 100.
  • In some embodiments, the infusion electrode 80 may be integrated with the body of the delivery catheter 100 such that the infusion electrode 80 extends distally within the sidewall 190 of the delivery catheter 100 rather than within the lumen 124 of the delivery catheter 100. In such embodiments, for example, the infusion electrode 80 may extend distally from the proximal end 110 of the delivery catheter 100 to a transmission portion adjacent the detachment zone 30. At least a region of the transmission portion may be exposed to the lumen 124 such that, when fluid 170 flows through the lumen 124 and the power supply 46 is providing a voltage across the first and second terminals 48, 47, an electrical current passes through the first terminal 48 of the power supply 46, the delivery electrode 82, the proximal region 31 of the delivery wire 44, the detachment zone 30, the fluid 170 in the lumen 124 of the delivery catheter 100, the transmission portion, the infusion electrode 80, and the second terminal 47 of the power supply 46.
  • In some embodiments, the exposed region of the transmission portion is located along the length of the delivery catheter 100 within 2 inches of the detachment zone 30. In some embodiments, the exposed region of the transmission portion is located along the length of the delivery catheter 100 within 1-2 inches of the detachment zone 30. In some embodiments, the exposed region of the transmission portion is located along the length of the delivery catheter 100 within 1 inch of the detachment zone 30.
  • In some embodiments, the transmission portion and the infusion electrode 80 are a single, continuous component or material (e.g., integral with one another), and the transmission portion may be a portion of the infusion electrode 80 that is exposed to the lumen 124. For example, in some embodiments the infusion electrode 80 may be an elongated, conductive member (e.g., a wire) that is insulated within the sidewall 190 of the delivery catheter 100, and the transmission portion is a portion of the conductive member that is exposed to the lumen 124 through the sidewall 190 within 2 inches of the detachment zone 30. In certain embodiments, the sidewall 190 of the delivery catheter 100 includes a coil and/or braid along its length that include one or more conductive materials. In such embodiments, a proximal end portion of the coil and/or braid can be electrically coupled to the second terminal 47 of the power source (directly or indirectly via one or more connectors) and a distal end portion of the braid and/or coil may be exposed through the sidewall 190 to the lumen 124 within 2 inches of the detachment zone. In some embodiments, a distal end portion of the braid and/or coil may be exposed through the sidewall 190 to the lumen 124 within 1-2 inches of the detachment zone, and in some embodiments within 1 inch of the detachment zone. As such, the transmission portion may be the exposed length of the coil and/or braid, and the infusion electrode 80 may be the length of the coil and/or braid between the second terminal 47 and the exposed portion.
  • In some embodiments, the transmission portion and the infusion electrode 80 are separate components that are electrically coupled to one another. For example, in some embodiments the infusion electrode 80 may be a first conductive element (e.g., a wire, a braid, a coil, etc.) that is insulated within the sidewall 190 of the delivery catheter 100, and the transmission portion is a second conductive element (e.g., all or part of a marker band, a braid, a coil, etc.) having at least a region exposed to the lumen 124 through the sidewall 190 within 2 inches of the detachment zone 30. In some embodiments, the second conductive element has at least a region exposed to the lumen 124 through the sidewall 190 within 1-2 inches of the detachment zone 30, and in some embodiments within 1 inch of the detachment zone. In any of the foregoing embodiments, a distal end portion of the infusion electrode 80 may be electrically coupled to a proximal end portion of the transmission portion.
  • FIGS. 7-9 illustrate various stages of an exemplifying method according to one or more embodiments of the subject technology. FIG. 7 illustrates an implant 20 inserted within the aneurysm 2. FIG. 8 illustrates a stage of detachment in progress FIG. 9 illustrates a stage following detachment of the implant 20 from the pusher assembly 12.
  • According to some embodiments, for example as shown in FIG. 7, the delivery catheter 100 is advanced to place its distal end 112 in the vicinity of a target site (e.g., an aneurysm 2). In addition to the components and steps shown herein, other components and stages may also be employed. For example, the delivery catheter 100 may be guided to the target site by a guide wire and/or a guide catheter, according to known techniques.
  • According to some embodiments, the implant 20 can be advanced over a guidewire (not shown) through the lumen 124 to the target site. For example, as shown in FIG. 7, the implant 20 can be placed within the aneurysm and deployed. As further shown in FIG. 7, the implant 20 is advanced from the delivery catheter 100 to the target site. Alternatively or in combination, the implant 20 may be placed at the target site, and the delivery catheter 100 may be subsequently advanced or retracted relative to the pusher assembly 12 while the pusher assembly 12 holds the implant 20 steady. The delivery catheter 100 may be positioned such that the detachment zone is entirely exposed, partially exposed, or not exposed by the delivery catheter 100. For example, the detachment zone 30 may be distal to, overlapping with, or proximal to the distal end 112 of the delivery catheter 100. In some embodiments, the detachment zone 30 can be longitudinally aligned with the distal end of the delivery catheter 100. Positioning of the delivery catheter 100 relative to the pusher assembly 12 (e.g., relative to the detachment zone 30) and/or implant 20 may be facilitated by components providing visualization. For example, a radiopaque marker of the delivery catheter 100 can be longitudinally aligned with a radiopaque marker of the pusher assembly 12 and/or the implant 20 to provide confirmation that the implant 20 is positioned outside of the delivery catheter 100.
  • According to some embodiments, for example as shown in FIG. 8, electrolytic detachment of the implant 20 from the pusher assembly 12 can be achieved. One or both of the detachment zone 30 and the infusion electrode 80 can be energized to apply electrical energy. For example, the detachment zone 30 and the infusion electrode 80 can be energized with electrical energy of opposite polarity to create a voltage potential and pass electrical current through the fluid 170 between the detachment zone 30 and the infusion electrode 80. While the electrical current can pass predominantly through the fluid 170, current induced by the voltage potential may also pass along other pathways. Fluids other than the fluid 170 from the fluid source 150 can contribute to an electrical pathway. For example, blood from the body of the patient may mix with the fluid 170 and form a portion of the pathway.
  • During detachment, a current source (e.g., the power supply 46) connected to the detachment zone 30 is activated and/or a current source connected to the infusion electrode 80 is activated. While one of the detachment zone 30 and the infusion electrode 80 are energized, the other can be energized with an opposite polarity or grounded. According to some embodiments, during operation, the detachment zone 30 and the infusion electrode 80 can each be multifunctional. For example, each can serve as either an active electrode or a ground electrode at different points in time as the treatment proceeds. By further example, each can serve as either a cathode or an anode at different points in time as the treatment proceeds. If desired, during the period of time that a voltage potential is formed, the polarity can be switched once or repeatedly, to create currents traveling in either direction across the gap between the detachment zone 30 and the infusion electrode 80.
  • According to some embodiments, for example as shown in FIG. 8, fluid flow 170 can be provided during electrolytic detachment of the implant 20 from the pusher assembly 12. For example, an infusion of fluid from the fluid source 150 by the pump 160 can be provided via the delivery catheter 100 past the detachment zone 30. The fluid flow 170 can be directed distally from the lumen 124 to a region distal to the distal end 112 of the delivery catheter 100. Alternatively the fluid flow 170 can be directed proximally into the lumen 124 from a region distal to the distal end 112 of the delivery catheter 100.
  • According to some embodiments, the fluid flow 170 may evacuate any bubbles that form near the detachment zone 30. The formation of bubbles can also change the dielectric characteristics of the vicinity of the detachment zone 30. For example, bubbles can serve as a dielectric material and electrically insulate the detachment zone 30 from the infusion electrode 80. Such a condition can create a dielectric region with an undesirably high breakdown voltage. The fluid flow 170 can refresh the fluid composition within the gap to maintain a clear conduction path.
  • According to some embodiments, the fluid flow 170 may evacuate debris from the vicinity of the detachment zone 30. For example, as portions of the detachment zone 30 are released into the vicinity of the detachment zone 30, the debris can form or facilitate a short circuit from the detachment zone 30 to other structures, thereby creating a conductive bridge and reducing the rate of electrolytic detachment of the detachment zone 30. The fluid flow 170 can remove the debris to maintain a clear pathway for electrical current between the detachment zone 30 and the infusion electrode 80.
  • According to some embodiments, the fluid flow 170 can be provided during part or all of an electrolytic detachment operation. For example, the fluid flow 170 may commence before, during, or after initial application of a voltage potential between the detachment zone 30 and the delivery catheter 100. By further example, the fluid flow 170 may cease before, during, or after termination of the voltage potential.
  • According to some embodiments, the fluid flow 170 can be provided intermittently based on conditions existing during the electrolytic detachment process. For example, the fluid flow 170 can be provided when and/or only when the power supply 46 outputs a voltage and/or current above and/or below a threshold. For example, if a controller of the power supply 46 detects an increase (e.g., short circuit) or decrease (e.g. open circuit) of current flow between the detachment zone 30 and the infusion electrode 80, the fluid flow 170 can be controllably provided until the current flow normalizes to a desired value or range of values, representative of efficient electrolytic corrosion. The flow of fluid can be continuous throughout a stage or an entirety of a process. The flow can have an increased rate during portions of a process to remove debris and reduce thrombus formation.
  • According to some embodiments, for example as shown in FIG. 9, full corrosion of the detachment zone 30 results in the implant 20 being entirely separated from the pusher assembly 12. Upon detachment, the fluid flow 170 can cease, and the pusher assembly 12 and the delivery catheter 100 can be retracted away from the target site and out of the patient, leaving the implant 20 at the target site.
  • Embodiments disclosed herein can be used in veterinary or human medicine and more particularly, for the endovascular treatment of intracranial aneurysms and acquired or innate arteriovenous blood vessel deformities and/or fistulas and/or for the embolization of tumors.
  • The apparatus and methods discussed herein are not limited to the deployment and use of an occluding device within any particular vessels, but can include any number of different types of vessels. For example, in some embodiments, vessels can include arteries or veins. In some embodiments, the vessels can be suprathoracic vessels (e.g., vessels in the neck or above), intrathoracic vessels (e.g., vessels in the thorax), subthoracic vessels (e.g., vessels in the abdominal area or below), lateral thoracic vessels (e.g., vessels to the sides of the thorax such as vessels in the shoulder area and beyond), or other types of vessels and/or branches thereof.
  • In some embodiments, the stent delivery systems disclosed herein can be deployed within superthoracic vessels. The suprathoracic vessels can include at least one of intracranial vessels, cerebral arteries, and/or any branches thereof. In some embodiments, the stent delivery systems disclosed herein can be deployed within intrathoracic vessels. The intrathoracic vessels can include the aorta or branches thereof. In some embodiments, the stent delivery systems disclosed herein can be deployed within subthoracic vessels. In some embodiments, the stent delivery systems disclosed herein can be deployed within lateral thoracic vessels.
  • The foregoing description is provided to enable a person skilled in the art to practice the various configurations described herein. While the subject technology has been particularly described with reference to the various figures and configurations, it should be understood that these are for illustration purposes only and should not be taken as limiting the scope of the subject technology.
  • There may be many other ways to implement the subject technology. Various functions and elements described herein may be partitioned differently from those shown without departing from the scope of the subject technology. Various modifications to these configurations will be readily apparent to those skilled in the art, and generic principles defined herein may be applied to other configurations. Thus, many changes and modifications may be made to the subject technology, by one having ordinary skill in the art, without departing from the scope of the subject technology.
  • A phrase such as “an aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all configurations, or one or more configurations. An aspect may provide one or more examples of the disclosure. A phrase such as “an aspect” may refer to one or more aspects and vice versa. A phrase such as “an embodiment” does not imply that such embodiment is essential to the subject technology or that such embodiment applies to all configurations of the subject technology. A disclosure relating to an embodiment may apply to all embodiments, or one or more embodiments. An embodiment may provide one or more examples of the disclosure. A phrase such “an embodiment” may refer to one or more embodiments and vice versa. A phrase such as “a configuration” does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology. A disclosure relating to a configuration may apply to all configurations, or one or more configurations. A configuration may provide one or more examples of the disclosure. A phrase such as “a configuration” may refer to one or more configurations and vice versa. It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplifying approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.
  • Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.
  • A reference to an element in the singular is not intended to mean “one and only one” unless specifically stated, but rather “one or more.” The term “some” refers to one or more. All structural and functional equivalents to the elements of the various configurations described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and intended to be encompassed by the subject technology. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.
  • While certain aspects and embodiments of the subject technology have been described, these have been presented by way of example only, and are not intended to limit the scope of the subject technology. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the subject technology.

Claims (20)

1. A method of delivering an implant, the method comprising:
positioning the implant at a target location within a patient, the implant being attached to a delivery wire by an electrolytically corrodible detachment zone;
applying a voltage potential between (i) a delivery electrode electrically coupled to the electrolytically corrodible detachment zone via the delivery wire and (ii) an infusion electrically coupled to the electrolytically corrodible detachment zone via a fluid from a fluid source disposed outside of the patient; and
while applying the voltage potential, flushing the fluid from the fluid source past the electrolytically corrodible detachment zone.
2. The method of claim 1, wherein the infusion electrode is disposed outside of the patient.
3. The method of claim 1, wherein positioning the implant comprises:
positioning a catheter with a proximal end region outside the patient and a distal end region at the target location; and
advancing the implant through a lumen of the catheter.
4. The method of claim 3, wherein applying the voltage potential comprises:
connecting the delivery electrode to a portion of the delivery wire disposed outside of the patient; and
connecting the infusion electrode to a portion of the catheter disposed outside of the patient.
5. The method of claim 1, wherein applying the voltage potential comprises:
applying a voltage potential between the delivery electrode and the infusion electrode.
6. The method of claim 1, wherein applying the voltage potential comprises:
connecting the delivery electrode to a portion of the delivery wire disposed outside of the patient; and
connecting the infusion electrode to a portion of the fluid source disposed outside of the patient.
7. The method of claim 1, wherein applying the voltage potential comprises applying the voltage potential until the detachment zone has corroded.
8. The method of claim 1, wherein the voltage potential is applied until the implant is separated from the delivery wire.
9. The method of claim 1, wherein the fluid is flushed until the implant is separated from the delivery wire.
10. The method of claim 1, wherein at least a portion of the delivery wire is electrically insulated on an outer surface thereof.
11. The method of claim 1, wherein the fluid comprises saline.
12. The method of claim 1, wherein positioning the implant at a target location is through a lumen of a catheter, and wherein a distal tip of the infusion electrode is positioned within the lumen within 2 inches of the detachment zone.
13. The method of claim 1, wherein positioning the implant at a target location is through a lumen of a catheter, and wherein a distal tip of the infusion electrode is positioned within the lumen within 1 inch of the detachment zone.
14. The method of claim 1, wherein the infusion electrode extends within the sidewall from the proximal end region of the catheter to the distal end region of the catheter.
15. The method of claim 13, wherein a portion of the infusion electrode is exposed through the sidewall within 2 inches of the detachment zone.
16. The method of claim 13, wherein a portion of the infusion electrode is exposed through the sidewall within 1 inch of the detachment zone.
17. A method of delivering an implant, the method comprising:
positioning the implant at a target location within a patient, the implant being attached to a delivery wire by an electrolytically corrodible detachment zone, the delivery wire extending through a lumen of a catheter;
applying a voltage potential between (i) a delivery electrode electrically coupled to the electrolytically corrodible detachment zone via the delivery wire and (ii) an infusion electrode integrated within the catheter and extending in a longitudinal direction, the infusion electrically coupled to the electrolytically corrodible detachment zone via a fluid within the catheter lumen; and
while applying the voltage potential, flushing the fluid from the fluid source past the electrolytically corrodible detachment zone.
18. The method of claim 17, wherein the infusion electrode extends within a sidewall of the catheter from a proximal end region of the catheter to a distal end region of the catheter.
19. The method of claim 18, wherein a portion of the infusion electrode is exposed through the sidewall within 2 inches of the detachment zone.
20. The method of claim 18, wherein a portion of the infusion electrode is exposed through the sidewall within 1 inch of the detachment zone.
US16/948,740 2016-06-27 2020-09-30 Electrolytic detachment with fluid electrical connection Pending US20210007753A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/948,740 US20210007753A1 (en) 2016-06-27 2020-09-30 Electrolytic detachment with fluid electrical connection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354939P 2016-06-27 2016-06-27
US15/619,774 US10828037B2 (en) 2016-06-27 2017-06-12 Electrolytic detachment with fluid electrical connection
US16/948,740 US20210007753A1 (en) 2016-06-27 2020-09-30 Electrolytic detachment with fluid electrical connection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/619,774 Division US10828037B2 (en) 2016-06-27 2017-06-12 Electrolytic detachment with fluid electrical connection

Publications (1)

Publication Number Publication Date
US20210007753A1 true US20210007753A1 (en) 2021-01-14

Family

ID=60675762

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/619,774 Active 2037-08-17 US10828037B2 (en) 2016-06-27 2017-06-12 Electrolytic detachment with fluid electrical connection
US16/948,740 Pending US20210007753A1 (en) 2016-06-27 2020-09-30 Electrolytic detachment with fluid electrical connection

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/619,774 Active 2037-08-17 US10828037B2 (en) 2016-06-27 2017-06-12 Electrolytic detachment with fluid electrical connection

Country Status (2)

Country Link
US (2) US10828037B2 (en)
WO (1) WO2018005113A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11051824B2 (en) * 2017-09-28 2021-07-06 Microvention, Inc. Embolic delivery
US10709463B2 (en) 2017-12-11 2020-07-14 Covidien Lp Electrically enhanced retrieval of material from vessel lumens
US11058444B2 (en) 2017-12-11 2021-07-13 Covidien Lp Electrically enhanced retrieval of material from vessel lumens
US11090071B2 (en) 2018-06-22 2021-08-17 Covidien Lp Electrically enhanced retrieval of material from vessel lumens
US11612430B2 (en) 2019-03-19 2023-03-28 Covidien Lp Electrically enhanced retrieval of material from vessel lumens
US11523838B2 (en) 2019-06-12 2022-12-13 Covidien Lp Retrieval of material from corporeal lumens
US11191558B2 (en) 2019-06-12 2021-12-07 Covidien Lp Retrieval of material from corporeal lumens
US11395668B2 (en) 2019-12-12 2022-07-26 Covidien Lp Electrically enhanced retrieval of material from vessel lumens
US11944374B2 (en) 2021-08-30 2024-04-02 Covidien Lp Electrical signals for retrieval of material from vessel lumens
CN114246711A (en) * 2021-12-02 2022-03-29 微创神通医疗科技(上海)有限公司 Push rod, releasing device and medical device
US20230240686A1 (en) * 2022-02-03 2023-08-03 Covidien Lp Occlusive devices with spiral struts for treating vascular defects
US20240032933A1 (en) * 2022-07-30 2024-02-01 Covidien Lp Devices, systems, and methods for treating aneurysms

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5941888A (en) * 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
US6059779A (en) * 1995-04-28 2000-05-09 Target Therapeutics, Inc. Delivery catheter for electrolytically detachable implant
US20030120300A1 (en) * 2001-12-20 2003-06-26 Scimed Life Systems, Inc. Detachable device with electrically responsive element
US6585748B1 (en) * 1997-07-18 2003-07-01 King's Healthcare Nhs Trust Of King's College Device for treating aneurysms
US20100094395A1 (en) * 2008-10-13 2010-04-15 Boston Scientific Scimed, Inc. Vaso-occlusive coil delivery system
US20130296917A1 (en) * 2012-05-04 2013-11-07 Interventco Llc Device and Method for Filling of Aneurysm or Body Cavity
US20150173772A1 (en) * 2013-12-20 2015-06-25 Microvention, Inc. Device Delivery System

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122136A (en) 1990-03-13 1992-06-16 The Regents Of The University Of California Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
USRE42756E1 (en) 1990-03-13 2011-09-27 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5354295A (en) 1990-03-13 1994-10-11 Target Therapeutics, Inc. In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US6425893B1 (en) 1990-03-13 2002-07-30 The Regents Of The University Of California Method and apparatus for fast electrolytic detachment of an implant
US6083220A (en) 1990-03-13 2000-07-04 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5851206A (en) 1990-03-13 1998-12-22 The Regents Of The University Of California Method and apparatus for endovascular thermal thrombosis and thermal cancer treatment
USRE42625E1 (en) 1990-03-13 2011-08-16 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5108407A (en) 1990-06-08 1992-04-28 Rush-Presbyterian St. Luke's Medical Center Method and apparatus for placement of an embolic coil
US5250071A (en) 1992-09-22 1993-10-05 Target Therapeutics, Inc. Detachable embolic coil assembly using interlocking clasps and method of use
US5706809A (en) 1993-01-29 1998-01-13 Cardima, Inc. Method and system for using multiple intravascular sensing devices to detect electrical activity
US5925059A (en) 1993-04-19 1999-07-20 Target Therapeutics, Inc. Detachable embolic coil assembly
US5800453A (en) 1993-04-19 1998-09-01 Target Therapeutics, Inc. Detachable embolic coil assembly using interlocking hooks and slots
US5370653A (en) 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
US5498227A (en) 1993-09-15 1996-03-12 Mawad; Michel E. Retrievable, shielded radiotherapy implant
US5423829A (en) 1993-11-03 1995-06-13 Target Therapeutics, Inc. Electrolytically severable joint for endovascular embolic devices
US5624449A (en) 1993-11-03 1997-04-29 Target Therapeutics Electrolytically severable joint for endovascular embolic devices
US5522836A (en) 1994-06-27 1996-06-04 Target Therapeutics, Inc. Electrolytically severable coil assembly with movable detachment point
DE4445715C2 (en) 1994-12-22 1998-04-09 Hans Dr Med Henkes Arrangement for inserting an implant into a blood vessel or into a body cavity
IL116561A0 (en) 1994-12-30 1996-03-31 Target Therapeutics Inc Severable joint for detachable devices placed within the body
CA2173023C (en) 1995-03-30 2001-08-28 David Kupiecki Liquid coils with secondary shape
WO1996033763A2 (en) * 1995-04-28 1996-10-31 Target Therapeutics, Inc. High performance braided catheter
US5853418A (en) 1995-06-30 1998-12-29 Target Therapeutics, Inc. Stretch resistant vaso-occlusive coils (II)
US6013084A (en) 1995-06-30 2000-01-11 Target Therapeutics, Inc. Stretch resistant vaso-occlusive coils (II)
US5743905A (en) 1995-07-07 1998-04-28 Target Therapeutics, Inc. Partially insulated occlusion device
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5658308A (en) 1995-12-04 1997-08-19 Target Therapeutics, Inc. Bioactive occlusion coil
US5749894A (en) 1996-01-18 1998-05-12 Target Therapeutics, Inc. Aneurysm closure method
US6168622B1 (en) 1996-01-24 2001-01-02 Microvena Corporation Method and apparatus for occluding aneurysms
US5980514A (en) 1996-07-26 1999-11-09 Target Therapeutics, Inc. Aneurysm closure device assembly
US5964797A (en) 1996-08-30 1999-10-12 Target Therapeutics, Inc. Electrolytically deployable braided vaso-occlusion device
US5690667A (en) 1996-09-26 1997-11-25 Target Therapeutics Vasoocclusion coil having a polymer tip
US5733329A (en) 1996-12-30 1998-03-31 Target Therapeutics, Inc. Vaso-occlusive coil with conical end
US5944114A (en) 1997-01-27 1999-08-31 Farley; Brent L. Devices for constraining wildfires
DE19703482A1 (en) 1997-01-31 1998-08-06 Ernst Peter Prof Dr M Strecker Stent
US5951599A (en) 1997-07-09 1999-09-14 Scimed Life Systems, Inc. Occlusion system for endovascular treatment of an aneurysm
US5928260A (en) 1997-07-10 1999-07-27 Scimed Life Systems, Inc. Removable occlusion system for aneurysm neck
EP1003422B1 (en) 1997-08-05 2006-06-14 Boston Scientific Limited Detachable aneurysm neck bridge
US6063070A (en) 1997-08-05 2000-05-16 Target Therapeutics, Inc. Detachable aneurysm neck bridge (II)
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
US5984929A (en) 1997-08-29 1999-11-16 Target Therapeutics, Inc. Fast detaching electronically isolated implant
US6156061A (en) 1997-08-29 2000-12-05 Target Therapeutics, Inc. Fast-detaching electrically insulated implant
US6146373A (en) 1997-10-17 2000-11-14 Micro Therapeutics, Inc. Catheter system and method for injection of a liquid embolic composition and a solidification agent
US6511468B1 (en) 1997-10-17 2003-01-28 Micro Therapeutics, Inc. Device and method for controlling injection of liquid embolic composition
US6241691B1 (en) 1997-12-05 2001-06-05 Micrus Corporation Coated superelastic stent
US6136015A (en) 1998-08-25 2000-10-24 Micrus Corporation Vasoocclusive coil
US5873907A (en) 1998-01-27 1999-02-23 Endotex Interventional Systems, Inc. Electrolytic stent delivery system and methods of use
US5935145A (en) 1998-02-13 1999-08-10 Target Therapeutics, Inc. Vaso-occlusive device with attached polymeric materials
US6077260A (en) 1998-02-19 2000-06-20 Target Therapeutics, Inc. Assembly containing an electrolytically severable joint for endovascular embolic devices
US6168615B1 (en) 1998-05-04 2001-01-02 Micrus Corporation Method and apparatus for occlusion and reinforcement of aneurysms
JP4037958B2 (en) 1998-05-11 2008-01-23 日清紡績株式会社 Thermosetting resin composition
US5935148A (en) 1998-06-24 1999-08-10 Target Therapeutics, Inc. Detachable, varying flexibility, aneurysm neck bridge
US6165193A (en) 1998-07-06 2000-12-26 Microvention, Inc. Vascular embolization with an expansible implant
US6478773B1 (en) 1998-12-21 2002-11-12 Micrus Corporation Apparatus for deployment of micro-coil using a catheter
US6296622B1 (en) 1998-12-21 2001-10-02 Micrus Corporation Endoluminal device delivery system using axially recovering shape memory material
DE69936869T2 (en) 1998-09-04 2008-05-15 Boston Scientific Ltd., St. Michael REMOVABLE SYSTEM FOR CLOSING AN ANEURYSMAS NECK
US6723112B2 (en) 1998-11-10 2004-04-20 Scimed Life Systems, Inc. Bioactive three loop coil
US6835185B2 (en) 1998-12-21 2004-12-28 Micrus Corporation Intravascular device deployment mechanism incorporating mechanical detachment
US7018401B1 (en) 1999-02-01 2006-03-28 Board Of Regents, The University Of Texas System Woven intravascular devices and methods for making the same and apparatus for delivery of the same
ATE377395T1 (en) 1999-06-02 2007-11-15 Sethel Interventional Inc INTRACORPORAL CLOSURE DEVICE
US6280457B1 (en) 1999-06-04 2001-08-28 Scimed Life Systems, Inc. Polymer covered vaso-occlusive devices and methods of producing such devices
US6309367B1 (en) 1999-07-23 2001-10-30 Neurovasx, Inc. Aneurysm shield
US6238403B1 (en) 1999-10-04 2001-05-29 Microvention, Inc. Filamentous embolic device with expansible elements
US6602261B2 (en) 1999-10-04 2003-08-05 Microvention, Inc. Filamentous embolic device with expansile elements
US8048104B2 (en) 2000-10-30 2011-11-01 Dendron Gmbh Device for the implantation of occlusion spirals
DE10010840A1 (en) 1999-10-30 2001-09-20 Dendron Gmbh Device for implanting occlusion coils uses coils electrolytically corrodable at several points at intervals so variable sized lengths can be separated by electrolysis
US6331184B1 (en) 1999-12-10 2001-12-18 Scimed Life Systems, Inc. Detachable covering for an implantable medical device
US7740637B2 (en) 2000-02-09 2010-06-22 Micrus Endovascular Corporation Apparatus and method for deployment of a therapeutic device using a catheter
US6632241B1 (en) 2000-03-22 2003-10-14 Endovascular Technologies, Inc. Self-expanding, pseudo-braided intravascular device
US6468301B1 (en) 2000-03-27 2002-10-22 Aga Medical Corporation Repositionable and recapturable vascular stent/graft
US20030176857A1 (en) 2000-07-26 2003-09-18 Lee Kyu Ho Assembly for embolic treatments
US6605101B1 (en) 2000-09-26 2003-08-12 Microvention, Inc. Microcoil vaso-occlusive device with multi-axis secondary configuration
US6416373B1 (en) 2000-10-12 2002-07-09 Bombardier Motor Corporation Of America Oil system vent with remote oil reservoir
US6743251B1 (en) 2000-11-15 2004-06-01 Scimed Life Systems, Inc. Implantable devices with polymeric detachment junction
US8721625B2 (en) 2001-01-26 2014-05-13 Cook Medical Technologies Llc Endovascular medical device with plurality of wires
US6494884B2 (en) 2001-02-09 2002-12-17 Concentric Medical, Inc. Methods and devices for delivering occlusion elements
US6878384B2 (en) 2001-03-13 2005-04-12 Microvention, Inc. Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use
DE10118017B4 (en) 2001-04-10 2017-04-13 Dendron Gmbh Occlusion coil and device for implantation of occlusion coils
CA2449055C (en) 2001-05-29 2010-03-02 Microvention, Inc. Method of manufacturing expansile filamentous embolization devices
US20040225279A1 (en) 2001-06-01 2004-11-11 Jean Raymond Detachable tip microcatheter for use of liquid embolic agents
US8715312B2 (en) 2001-07-20 2014-05-06 Microvention, Inc. Aneurysm treatment device and method of use
US7572288B2 (en) 2001-07-20 2009-08-11 Microvention, Inc. Aneurysm treatment device and method of use
US8252040B2 (en) 2001-07-20 2012-08-28 Microvention, Inc. Aneurysm treatment device and method of use
US20030028209A1 (en) 2001-07-31 2003-02-06 Clifford Teoh Expandable body cavity liner device
US7687053B2 (en) 2001-08-20 2010-03-30 Boston Scientific Scimed, Inc. Embolic compositions with non-cyanoacrylate rheology modifying agents
EP1420701B1 (en) 2001-08-27 2015-01-14 Dendron GmbH Device for the implantation of occlusion means
US6878151B2 (en) 2001-09-27 2005-04-12 Scimed Life Systems, Inc. Medical retrieval device
DE10155191A1 (en) 2001-11-12 2003-05-22 Dendron Gmbh Medical implant
US6960215B2 (en) 2002-05-08 2005-11-01 Boston Scientific Scimed, Inc. Tactical detachable anatomic containment device and therapeutic treatment system
US7166122B2 (en) 2002-06-27 2007-01-23 Boston Scientific Scimed, Inc. Anchor assemblies in stretch-resistant vaso-occlusive coils
DE10233085B4 (en) 2002-07-19 2014-02-20 Dendron Gmbh Stent with guide wire
US7169172B2 (en) 2002-11-01 2007-01-30 Counter Clockwise, Inc. Method and apparatus for caged stent delivery
US7229454B2 (en) 2003-01-07 2007-06-12 Boston Scientific Scimed, Inc. Occlusive cinching devices and methods of use
US20040193178A1 (en) 2003-03-26 2004-09-30 Cardiomind, Inc. Multiple joint implant delivery systems for sequentially-controlled implant deployment
US7651513B2 (en) 2003-04-03 2010-01-26 Boston Scientific Scimed, Inc. Flexible embolic device delivery system
US7569626B2 (en) 2003-06-05 2009-08-04 Dfine, Inc. Polymer composites for biomedical applications and methods of making
US20070135907A1 (en) 2003-10-02 2007-06-14 The Regents Of The University Of California Stent with expandable foam
US8157855B2 (en) 2003-12-05 2012-04-17 Boston Scientific Scimed, Inc. Detachable segment stent
DE102004003265A1 (en) 2004-01-21 2005-08-11 Dendron Gmbh Device for the implantation of electrically isolated occlusion coils
WO2005094725A1 (en) 2004-03-31 2005-10-13 Merlin Md Pte Ltd A method for treating aneurysms
US8500751B2 (en) 2004-03-31 2013-08-06 Merlin Md Pte Ltd Medical device
EP1761178B1 (en) 2004-05-21 2010-12-08 Micro Therapeutics, Inc. Metallic coils enlaced with biological or biodegradable or synthetic polymers or fibers for embolization of a body cavity
WO2006032289A1 (en) 2004-09-22 2006-03-30 Dendron Gmbh Medical implant
WO2006032291A1 (en) 2004-09-22 2006-03-30 Dendron Gmbh Micro-spiral implantation device
CA2585147A1 (en) 2004-11-09 2006-05-18 Boston Scientific Limited Vaso-occlusive devices comprising complex-shape proximal portion and smaller diameter distal portion
US7608089B2 (en) 2004-12-22 2009-10-27 Boston Scientific Scimed, Inc. Vaso-occlusive device having pivotable coupling
US20060155323A1 (en) 2005-01-07 2006-07-13 Porter Stephen C Intra-aneurysm devices
EP1855600B1 (en) 2005-02-04 2011-06-29 Zuli Holdings, Ltd. A device for the treatment of an aneurysm
US20060200234A1 (en) 2005-03-03 2006-09-07 Hines Richard A Endovascular aneurysm treatment device and delivery system
US20060206199A1 (en) 2005-03-12 2006-09-14 Churchwell Stacey D Aneurysm treatment devices
DE102005019782A1 (en) 2005-04-28 2006-11-09 Dendron Gmbh Device for implantation of occlusion coils with internal securing means
JP4872913B2 (en) 2005-05-24 2012-02-08 株式会社カネカ Medical wire
US20060271097A1 (en) 2005-05-31 2006-11-30 Kamal Ramzipoor Electrolytically detachable implantable devices
US8641746B2 (en) 2005-05-31 2014-02-04 J.W. Medical Systems Ltd. In situ stent formation
US8002789B2 (en) 2005-05-31 2011-08-23 Stryker Corporation Stretch-resistant vaso-occlusive devices with flexible detachment junctions
US20070073334A1 (en) 2005-09-29 2007-03-29 Kamal Ramzipoor Combined electrolytic and mechanical separation background
AU2006304660B2 (en) 2005-10-19 2013-10-24 Pulsar Vascular, Inc. Methods and systems for endovascularly clipping and repairing lumen and tissue defects
US20070100414A1 (en) 2005-11-02 2007-05-03 Cardiomind, Inc. Indirect-release electrolytic implant delivery systems
AU2006330786B2 (en) 2005-11-17 2012-02-02 Microvention, Inc. Three-dimensional complex coil
US8998926B2 (en) 2006-04-06 2015-04-07 DePuy Synthes Products, LLC Heat detachable coil
US8777979B2 (en) 2006-04-17 2014-07-15 Covidien Lp System and method for mechanically positioning intravascular implants
CN101448464B (en) 2006-04-17 2011-05-04 微治疗公司 System and method for mechanically positioning intravascular implants
WO2007134266A2 (en) 2006-05-12 2007-11-22 Electroformed Stents, Inc. Exclusion device and system for delivery
EP2101682A4 (en) 2006-12-15 2017-03-01 Biosensors International Group, Ltd. Stent systems
KR20100015520A (en) 2007-03-13 2010-02-12 마이크로 테라퓨틱스 인코포레이티드 An implant including a coil and a stretch-resistant member
US8801747B2 (en) 2007-03-13 2014-08-12 Covidien Lp Implant, a mandrel, and a method of forming an implant
US8425542B2 (en) 2007-04-27 2013-04-23 Wisconsin Alumni Research Foundation Aneurysm occlusion device containing bioactive and biocompatible copolymer shell and biocompatible metallic frame member
US20080287982A1 (en) * 2007-05-16 2008-11-20 Boston Scientific Scimed, Inc. Catheters for electrolytically detachable embolic devices
US8221483B2 (en) * 2007-05-18 2012-07-17 Stryker Corporation Medical implant detachment systems and methods
US20110022149A1 (en) 2007-06-04 2011-01-27 Cox Brian J Methods and devices for treatment of vascular defects
ES2397010T3 (en) 2007-12-03 2013-03-04 Stryker Corporation Implantable device with electrolytically separable junction that has multiple thin wires
US20090227976A1 (en) 2008-03-05 2009-09-10 Calabria Marie F Multiple biocompatible polymeric strand aneurysm embolization system and method
US10028747B2 (en) 2008-05-01 2018-07-24 Aneuclose Llc Coils with a series of proximally-and-distally-connected loops for occluding a cerebral aneurysm
US20160206321A1 (en) 2008-05-01 2016-07-21 Aneuclose Llc Aneurysm Occlusion Device with Sequence of Shape-Changing Embolic Members
US10716573B2 (en) 2008-05-01 2020-07-21 Aneuclose Janjua aneurysm net with a resilient neck-bridging portion for occluding a cerebral aneurysm
CA2722672C (en) 2008-05-02 2019-10-22 Sequent Medical Inc. Filamentary devices for treatment of vascular defects
AU2009274126A1 (en) 2008-07-22 2010-01-28 Covidien Lp Vascular remodeling device
WO2010022180A1 (en) 2008-08-19 2010-02-25 Micro Therapeutics, Inc. Detachable tip microcatheter
EP2334242B1 (en) 2008-09-09 2014-11-26 Boston Scientific Scimed, Inc. Composite detachment mechanisms
WO2010048177A2 (en) 2008-10-20 2010-04-29 IMDS, Inc. Systems and methods for aneurysm treatment and vessel occlusion
US9211202B2 (en) 2008-10-24 2015-12-15 Wisconsin Alumni Research Foundation Apparatus and method for treating an aneurysm
EP2403439B1 (en) 2009-03-06 2016-07-20 The Regents of The University of California Thin film vascular stent and biocompatible surface treatment
US20100256666A1 (en) 2009-04-06 2010-10-07 Boston Scientific Scimed, Inc. Delivery wire for occlusive device delivery system
EP2419166B1 (en) 2009-04-15 2017-11-22 MicroVention, Inc. Implant delivery system
US9314250B2 (en) 2009-04-16 2016-04-19 Stryker Corporation Electrical contact for occlusive device delivery system
US8398671B2 (en) 2009-04-16 2013-03-19 Stryker Corporation Electrical contact for occlusive device delivery system
US8657870B2 (en) 2009-06-26 2014-02-25 Biosensors International Group, Ltd. Implant delivery apparatus and methods with electrolytic release
WO2011031548A2 (en) 2009-08-27 2011-03-17 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
WO2011053625A1 (en) 2009-11-02 2011-05-05 Boston Scientific Scimed, Inc. Delivery wire assembly for occlusive device delivery system
DE102009056449A1 (en) 2009-12-01 2011-06-09 Acandis Gmbh & Co. Kg Medical device
US8906057B2 (en) 2010-01-04 2014-12-09 Aneuclose Llc Aneurysm embolization by rotational accumulation of mass
US8926681B2 (en) 2010-01-28 2015-01-06 Covidien Lp Vascular remodeling device
DE102010021947A1 (en) 2010-05-28 2011-12-01 Phenox Gmbh implant replacement
US9247942B2 (en) 2010-06-29 2016-02-02 Artventive Medical Group, Inc. Reversible tubal contraceptive device
DE102010044746A1 (en) 2010-09-08 2012-03-08 Phenox Gmbh Implant for influencing the blood flow in arteriovenous malformations
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
CN103237526B (en) 2010-12-06 2015-12-02 科维蒂恩有限合伙公司 Vascular remodeling device
RU2018131107A (en) 2011-01-17 2018-10-31 Метэктив Медикал, Инк. DEVICE AND METHOD OF DELIVERY OF SEPARABLE METAL CYLINDER
WO2012109367A1 (en) 2011-02-10 2012-08-16 Stryker Corporation Vaso-occlusive device delivery system
DE102011011869A1 (en) 2011-02-22 2012-08-23 Phenox Gmbh implant
WO2012118957A2 (en) 2011-03-02 2012-09-07 Eskridge Joe Michael Endovascular closure system
US10028745B2 (en) 2011-03-30 2018-07-24 Noha, Llc Advanced endovascular clip and method of using same
EP2693981A4 (en) 2011-04-01 2015-07-01 Univ Cornell Method and apparatus for restricting flow through an opening in the side wall of a body lumen, and/or for reinforcing a weakness in the side wall of a body lumen, while still maintaining substantially normal flow through the body lumen
JP6061432B2 (en) 2011-06-03 2017-01-18 コヴィディエン リミテッド パートナーシップ Embolization implant and system for arterial occlusion
US20120316632A1 (en) 2011-06-13 2012-12-13 Bulang Gao Retrievable covered stent for bifurcation aneurysms
KR102005053B1 (en) 2012-01-17 2019-07-29 메타랙티브 메디컬, 인크. Expandable body device and method of use
EP2668914A1 (en) 2012-06-01 2013-12-04 Acandis GmbH & Co. KG Implant system
US9326774B2 (en) 2012-08-03 2016-05-03 Covidien Lp Device for implantation of medical devices
WO2014028913A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of California Dual rotational stent apparatus and method for endovascular treatment of aneurysms
WO2014029835A1 (en) 2012-08-22 2014-02-27 Phenox Gmbh Implant
CN104955420B (en) 2012-10-31 2018-02-23 艾维斯科神经血管有限合伙公司 Vascular endoprostheses
US10039536B2 (en) 2012-11-16 2018-08-07 W. L. Gore & Associates, Inc. Implantable medical device deployment system
EP2967575B1 (en) 2013-03-14 2019-07-31 Stryker Corporation Vaso-occlusive device delivery system
US9539011B2 (en) 2013-03-14 2017-01-10 Stryker Corporation Vaso-occlusive device delivery system
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
US20140316012A1 (en) 2013-03-15 2014-10-23 Toby Freyman In-Situ Forming Foams for Embolizing or Occluding a Cavity
US9907684B2 (en) 2013-05-08 2018-03-06 Aneuclose Llc Method of radially-asymmetric stent expansion
JP6359664B2 (en) 2013-08-20 2018-07-18 ストライカー コーポレイションStryker Corporation Vascular occlusive device delivery system
CN110013284B (en) 2013-09-03 2022-04-15 马建录 Detachment mechanism for implantable devices
WO2015073704A1 (en) 2013-11-13 2015-05-21 Covidien Lp Galvanically assisted attachment of medical devices to thrombus
GB2520482B (en) 2013-11-15 2015-12-23 Cook Medical Technologies Llc Aneurysm closure device
JP5695259B1 (en) 2014-02-19 2015-04-01 株式会社World Medish High flexibility stent
US20160066921A1 (en) 2014-02-21 2016-03-10 Neuravi Limited DEVICE AND METHOD FOR ENDOVASCULAR TREATMENT OF ANEURYSMS USING EMBOLIC ePTFE
EP4218618A3 (en) 2014-05-12 2023-08-23 Jeffrey E. Thomas Photon-activatable gel coated intracranial stent and embolic coil
US10182801B2 (en) 2014-05-16 2019-01-22 Silk Road Medical, Inc. Vessel access and closure assist system and method
WO2016108241A1 (en) 2014-12-31 2016-07-07 Endostream Medical Ltd. Device for restricting blood flow to aneurysms
US9999413B2 (en) 2015-01-20 2018-06-19 Neurogami Medical, Inc. Micrograft for the treatment of intracranial aneurysms and method for use
CN107530523B (en) 2015-02-25 2021-03-19 盖乐西医疗公司 System for treating aneurysm
US20160331377A1 (en) * 2015-05-11 2016-11-17 Covidien Lp Electrolytic detachment with flush system for implant delivery
US10814045B2 (en) 2015-10-30 2020-10-27 Balt Usa Devices and methods for aneurysm treatment
US10743883B2 (en) 2015-12-30 2020-08-18 Stryker European Holdings I, Llc Embolic devices and methods of manufacturing same
US20180049859A1 (en) 2016-08-16 2018-02-22 Spartan Micro, Inc. Intravascular flow diversion devices
WO2018051187A1 (en) 2016-09-14 2018-03-22 Medinol Ltd. Aneurysm closure device
CN108056798B (en) 2016-11-08 2021-06-04 艾柯医疗器械(北京)有限公司 Support pushing system, corresponding blood flow guiding device and blood flow guiding device assembling method
US20180193024A1 (en) 2016-12-05 2018-07-12 Daniel E. Walzman Alternative us of hydrogel intrasaccular occlusion device with center supporting bar for structrual support
WO2018112203A1 (en) 2016-12-14 2018-06-21 eLum Technologies, Inc. Electrospun stents, flow diverters, and occlusion devices and methods of making the same
CN110381855B (en) 2017-01-06 2023-07-04 因赛普特有限责任公司 Antithrombotic coating for aneurysm treatment devices
GB2558920A (en) 2017-01-20 2018-07-25 Cook Medical Technologies Llc Aneurysm treatment apparatus
ES2929060T3 (en) 2017-08-17 2022-11-24 Arissa Medical Inc flow attenuation device

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6059779A (en) * 1995-04-28 2000-05-09 Target Therapeutics, Inc. Delivery catheter for electrolytically detachable implant
US6585748B1 (en) * 1997-07-18 2003-07-01 King's Healthcare Nhs Trust Of King's College Device for treating aneurysms
US5941888A (en) * 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
US20030120300A1 (en) * 2001-12-20 2003-06-26 Scimed Life Systems, Inc. Detachable device with electrically responsive element
US20100094395A1 (en) * 2008-10-13 2010-04-15 Boston Scientific Scimed, Inc. Vaso-occlusive coil delivery system
US20130296917A1 (en) * 2012-05-04 2013-11-07 Interventco Llc Device and Method for Filling of Aneurysm or Body Cavity
US20150173772A1 (en) * 2013-12-20 2015-06-25 Microvention, Inc. Device Delivery System

Also Published As

Publication number Publication date
US10828037B2 (en) 2020-11-10
WO2018005113A1 (en) 2018-01-04
US20170367707A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
US20210007753A1 (en) Electrolytic detachment with fluid electrical connection
EP3809990B1 (en) Electrically enhanced retrieval of material from vessel lumens
EP3092957A1 (en) Electrolytic detachment with flush system for implant delivery
AU2016256789B2 (en) Detachable metal balloon delivery device and method
AU2019203321B2 (en) Expandable body device and method of use
JPH08322941A (en) Transmitting catheter for electrolytically releasable implant
US20210000477A1 (en) Electrolytic detachment for implantable devices
US20090306701A1 (en) Vascular access sheath with integrated return electrode
EP4059451A1 (en) Medical treatment system
US20230263649A1 (en) Endovascular prosthesis delivery system

Legal Events

Date Code Title Description
AS Assignment

Owner name: COVIDIEN LP, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DIVINO, VINCENT;REEL/FRAME:053934/0187

Effective date: 20160627

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED